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ABSTRACT
Acute kidney injury and chronic kidney disease are becoming more prevalent and have
high morbidity and mortality, and despite several therapies targeted towards treating or
preventing kidney injury, outcomes have been unchanged for many years. Calciumindependent phospholipase A 2y (iPLA2y) is one of seven Ca2+-independent PLA2
enzymes and represents a potential therapeutic target in kidney disease because of its
unique

subcellular

localization

and

its

potential

as

the

putative

membrane

remodeling/repair enzyme. Studies in our laboratory suggest iPLA2Y is cytoprotective
during oxidant injury by preventing and/or repairing oxidant-induced lipid peroxidation
and pointed to ER- iPLA2Y as the major component of membrane repair and remodeling.
The goals of these studies are to understand the role of ER- iPLA 2y in oxidant-induced
ER lipid peroxidation, Ca2+ release, loss of lipid homeostasis, and renal cell death.

Our

studies in isolated microsomes (ER) provide evidence that inhibition of ERiPLA2¥ results in the potentiation of oxidant-induced lipid peroxidation. Studies in renal
proximal tubule cells confirmed that iPLA2¥ is protective of oxidant-induced lipid
peroxidation and genetic ablation of iPLA2¥ in mice resulted in oxidant injury (lipid
peroxidatioh and mitochondrial DNA damage). To determine the role of ER- iPLA2¥ in
oxidant-induced Ca2+ release we developed assays to measure ER Ca2+ release from

IV

isolated microsomes and in RPTC uSIng Ca2+-sensitive fluorophores.

These studies

showed ER- iPLA21 prevented oxidant-induced ER Ca2+ release.
To determine the role of iPLA21 in oxidant-induced loss of lipid homeostasis, we
employed electron spray ionization-mass spectrometry (ESI-MS) to measure lipid
changes (phospholipids and fatty acids) in isolated micro somes, RPTC, and
iPLAtt KO mouse urine.

These studies provide evidence that ER- iPLA2Y mediates

oxidant-induced fatty acid release (oxidized and/or unsaturated) in isolated microsomes;
iPLA2y inhibition results in the build-up several phospholipids within renal cell
membranes;

and

genetic

ablation

iPLA 2y in

of

mIce

results

In

decreased

phosphatidylcholine containing phospholipids and increased fatty acids with methyl or
keto additions (likely lipid hydroperoxides) in mouse urine.
Our studies in RPTC demonstrated ER- iPLA21 protects renal cell from oxidant-induced
necrotic cell death by preventing ER membrane disruption and subsequent Ca2+ release.
We report the first in vivo studies suggesting that genetic ablation of iPLA2Y results in
kidney oxidant injury, induces compensatory mitochondrial changes and upregulation of
antioxidant stress pathways, however does not result measurable loss of kidney function.
Together these data support our previous findings that iPLA21 is cytoprotective in renal
cells and provide evidence that iPLA2y is critical for the prevention and/or repair of lipid
peroxidation in oxidative kidney injury.

v

Chapter 1
Review of Acute Renal Failure and Phospholipase A2 Biology

Kidney Function and Dysfunction. The kidneys are involved many functions including
water and electrolyte balance, regulation of arterial blood pressure, regulation of blood
cell synthesis, vitamin D production and fasting-induced gluconeogenesis [1].

The

kidneys are also responsible for the removal of water soluble waste products, such as
blood urea nitrogen (BUN) and creatinine, and xenobiotics, such as cisplatin and
aminoglycosides. Impaired kidney function, resulting in loss of electrolyte and water
balance and the build up of these compounds, results in neurological disturbances (ie
delirium, coma, and seizure), cardiac arrhythmias, fatigue, edema, and hypertension.
Complications from loss of kidney function result in significant morbidity and mortality.

Acute Kidney Injury. Acute kidney injury (AKI), in the clinical setting, is generally
diagnosed based upon an abrupt increase in serum creatinine (SCr) within the setting of
clinical symptoms such as nausea, vomiting, fatigue, and/or edema. This syndrome was
once termed acute renal failure until a more strict and accurate definition was adopted.
AKI requires a greater than 0.3 mg/dl (425 mmolll) rise or a > 50% increase in serum
creatinine, oliguria (a reduction in urine output <0.5 mllkg/h for greater than 6 h, or an
acute palliative need for dialysis [2]. The most recent criteria for defining the severity of
AKI stratifies the stages of injury from a minor insult causing minimal damage to
significant injury resulting in End-Stage Renal Disease (ESRD) [3]. These criteria are
termed RIFLE (Risk, Injury, Failure, Loss, and ESRD) and were developed because the
1

progression of AKI correlates well, clinically, with morbidity and mortality (Figure 1-1)

[4].

RIFLE
Crl GFR Criteria

Urine Output (UO) Criteria

Increased Cr x1.S

UO <0.5 mllkg/hr
x 6 hr

or

Risk

GFR decreases >250/0
Increased Cr x 2

UO <0.5 mllkg/hr
x 12 hr

or

Injury

GFR decreases >500/0

-Failure

Increased Cr x 3
or
GFR decreases >750/0
or
Cr~ 4 mg/dl
(with acute rise
of;Z; 0.5 mg/dl)

1:085

-ESRD

UO <0.3 mVkg/hr

x24 hr
or
anuria x 12 hr

Persistent ARF =
complete loss of renal function
for> 4 weeks
End Stage Renal
Disease

Figure 1-1. The RIFLE classification. The RIFLE criteria stratifies the stage of insult
from minor to major resulting in ESRD. The shape of the figure reflects the incidence of
patients within each stage. Importantly, more patients will be included in the mild
category while the bottom criteria are more strict and therefore more specific. GFR,
glomerular filtration rate; ARF, acute renal failure, ESRD, end stage renal disease. From
Bellomo et al [3].
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AKI Morbidity and Mortality.

AKI is associated with significant morbidity and

mortality. Epidemiological studies revealed that most AKI cases occur in hospitalized
patients and more specifically, patients in intensive care unit (ICU) [5]. ICU patients
with AKI are associated with as high as 90% mortality rates, presumably due to the
presence co-morbidities, including liverlheart failure and sepsis [6]. Although AKI is
associated with co-morbidities and the presence of other diseases may influence mortality
rates, AKI is independently associated with increased mortality in epidemiological
studies that adjust for the contribution of co-mobidities [7].

The mortality rate in

uncomplicated AKI is estimated to be as high as 23%. Mortality rates range from 1080% depending on the population studied (from uncomplicated AKI to those patients
requiring renal replacement therapy) [8-9].

Reliable statistics on incidence, cost, and mortality associated with AKI are hard to assess
because the numbers are inherently dependent on the population studied and incidence is
often tied with other disease states.

However, retrospective studies from in-patient

hospital records estimate the incidence rate to be approximately 5-7% (approximately 1%
community-acquired), and this number increases to approximately 20% in critically-ill
patients [10] A more useful and likely more appropriate assessment of the contribution
of AKI to poor health outcomes would be to quantify the added mortality, length of stay
and cost attributed to hospital-acquired AKI.

One study examining the data by

incremental changes in serum creatinine, found that even a moderate change in serum
creatinine (0.3 - 0.4 mg/dl) resulted in a 70% increase in risk of death, a 3.5 day increase
in length of stay, and a $9000 increase in health care associated costs [11].
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These

numbers were greatly increased when considering more robust changes In serum
creatinine (0.5 - 2.0 mg!dl increases).

AKI and Chronic Kidney Disease. Recent studies suggest AKI contributes to incident

and prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Approximately 10-40 million adults have CKD and over one half million were treated for
ESRD via dialysis or kidney transplantation in the US in 2007 [12]. The number of
patient with ESRD is projected to increase to 0.8 million by 2020. Additionally, there
has been a considerable increase in the incidence of AKI, which appears to be related to
the increased number of invasive medical and surgical procedures in the management of
critically ill elderly patients. In summary, AKI is responsible for significant increases in
morbidity, mortality, health care costs, and length of stay of both hospitalized/criticallyill patients and in patients presenting with AKI as a primary diagnosis.

Treatments for AKI.

Clinical treatment options for AKI are limited to supportive

measures including maintenance of intravascular volume, blood pressure regulation,
immediate discontinuation of suspected nephrotoxic drugs and correction of electrolyte
abnormalities [2]. Hyperkalemia is a common consequence of AKI, which can lead to
life threatening arrhythmias.

Potassium binding resins, fluid maintenance, and dietary

restriction are first line treatments for hyperkalemia associated with AKI [2].
Unfortunately, dialysis and kidney transplant have remained the gold standard of care for
the treatment of AKI for over 40 years and there has been no improvement in health
outcomes. Continuous renal replacement therapy (CRRT) and intermittent hemodialysis
4

cost approximately $4000/week and $1000/week, respectively while kidney transplant
carries with it it's own risks and co-morbidities such as the necessary immunosuppression
and related complications [13]. Several new agents have been proposed for the treatment
of AKI and target the many components contributing to kidney injury. Unfortunately,
while these treatment approaches seem promising in the laboratory setting, none have
contributed significantly to outcomes in clinical trials (Figure 1-2) [14].

• Antiapoptosis/necrosis agents
(>rCaspase inhibitors
¢ M in ocycIi ne
<) Pifithrin-a (p53 inhibitor)
(>PARP inhibitor
• Antisepsis
vActivated protein C
• Growth factors
(> Recombinant erythropoietin
• Vasodilators
<>Carbon monoxide release compounds
<> Bili rubin
• Anti-inflammatory drugs
'vSphingos,ine-1-phosphate analogues
<) Adenosine 2A agonists
¢Adenosine analogues
~}iNOS inhibitors
(>Fibrates
'0' Th iazolid in ediones
<) Alkaline phosphatase
• Cel~l-based therapies
(t M2 macrophages
<.> Regulatory T cells
<)80ne marrow multipotent stromal cells
Figure 1-2 Proposed Treatment Strategies for AKI. Many therapeutics have been
developed but none have resulted in significant improvement in clinical outcomes.
Adapted from Kinsey and Okusa, 2011 [14].
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Causes of AKI There are three major causes of AKI or ARF, classified as prerenal,
intrarenal and postrenal. Prerenal ARF is characterized by decreased blood flow to the
kidney secondary to decreased intravascular volume (ie. dehydration from excessive
diuresis, vomiting, and/or diarrhea) or decreased blood flow (ie. renal artery stenosis,
liver and heart failure, and shock associated loss of intravascular pressure) [2].

The

widely used medications, non-steroidal anti-inflammatory drugs (NSAIDs) and
angiotensin-converting enzyme inhibitors (ACEIs) can cause prerenal ARF by decreasing
the pressure in Bowman's capsule.

NSAIDs block the production of vasodilatory

prostaglandins and drive the production of thromboxane A2 causing the vasoconstriction
of afferent arterioles resulting in decreased blood flow into the capsule in the absence of
compensatory changes within the efferent arterioles leading to decreasing glomerular
pressure and glomerular filtration rate (GFR). ACEIs decrease levels of angiotensin II
resulting in dilation of efferent arterioles in the absence of increased blood flow into the
glomerulus through the afferent arterioles resulting in a similar drop in glomerular
pressure and GFR [15]. Pre-renal failure accounts for 40-70% of all renal failure and is
primarily observed in the community setting and upon admission into the hospital [16].
Clinically, pre-renal failure may be diagnosed by measuring urine and serum electrolytes
and creatinine and calculating the Fractional Excretion of Sodium (FENA). A FENA
value of less that 1% is suggestive of a pre-renal component of kidney dysfunction.

Post-renal ARF can be identified by an obstruction of urine outflow from the kidneys.
Obstruction may be caused by anatomical obstruction (developmental abnormalities,
6

strictures, benign prostatic hypertrophy, abdominal aortic aneurysms, or tumors) or
physical obstruction (ie. kidney stones, cellular debris or catheters) [17]. The extent of
damage to the kidney and therefore risk of end stage renal disease is proportional to the
extent of obstruction and the length of time the obstruction is present [2]. Anatomical
malformations, hyperkalemia, and other metabolic disturbances are common sequelae of
post-renal obstruction and should be monitored closely and treated promptly.

Intra-renal ARF is a result of dysfunction within the kidney and is divided into 4 groups
characterized by the anatomical region most significantly affected (glomerular,
interstitial, vascular and tubular).

Intrarenal ARF is sometimes used interchangeably

with acute tubular necrosis (ATN), although necrosis does not seem to be the only
underlying mechanism of cell death.

Intrarenal ARF is the most common cause of

kidney failure in the hospital setting [2].

Glomerular causes of ARF are relatively uncommon and are often associated with
immunological disorders such as systemic lupus erythematosus, Goodpasture's disease,
and other nephritic/nephrotic disorders. Systemic findings such as fever, arthritis and
rash are commonly present in patients with glomerular ARF [2]. Interstitial ARF is less
well understood, but is often caused by infection, autoimmune diseases or allergic
reaction to several drugs (ie. allopurinol; cephalosporins; ciprofloxacin; NSAIDs;
penicillins; sulfonamides and thiazide diuretics) [2]. Vascular ARF results from renal
artery stenosis or occlusion of smaller vessels inside the kidney. Because of the apparent
overlap in the causes of ARF and their classification, grouping is becoming less relevant,
7

but the mechanism of injury has become more important to understanding the etiology of
the disease.

Acute Tubular Necrosis. Although ATN is often used interchangeably with intra-renal
failure, necrosis is often not the only and sometimes not the major mechanism of cell
death. However, ATN is characterized by injury to and death of tubular epithelial cells.
Histological findings associated with A TN include: loss of brush border, thinning of the
tubular epithelial cell layer, interstitial edema, sloughing of cells into the lumen of the
tubule and tubular dilation (Figure 1-3) [18].

ATN is most commonly caused by

ischemia, ischemiaireperfusion, anoxia, or drug and toxicant injury.
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Figure 1-3. Representative histology (hematoxin and eosin stain) of a normal kidney
and of a kidney exhibiting acute tubular necrosis. i. Normal kidney cortex
morphology. Ischemialreperfusion-induced acute tubular necrosis at 24 h (ii), 72 h (iii),
or 144 h (iv) after ischemia-reperfusion injury at 40X magnification. Morphology
consistent with acute tubular necrosis including tubular dilation, loss of brush border and
increased space between tubules. From Funk and Schnellmann, 2011 [19].

nephrotoxic drugs or chemicals [20-21]. Proximal tubule cells are especially sensitive to
insult because of their high energy demand secondary to their extensive ATP-dependent
transport capacity.

Renal proximal tubule cells lack the capability of producing

glycolytic ATP during periods of ischemia [22]. Several drugs selectively target RPTC
9

because, in the process of transporting nephrotoxic drugs into and out of the urIne,
intracellular concentrations of these drugs reach high levels. Aminoglycoside antibiotics
and anticancer drugs such as cisplatin are examples of agents that are directly toxic to
RPTC and induce ARF. Mercury and cadmium are examples of environmental toxins that
can induce cell death ofRPTC and precipitate ARF [23].

There are 3 stages of ATN termed: initiation, maintenance and recovery. Initiation is the
time immediately following toxicant exposure or ischemia and GFR is severely reduced.
The maintenance phase can last up to 2 weeks and is associated with a continued
reduction in GFR, decreased urine output and increased BUN and SCr. The kidney has
restorative and regenerative capacities very similar to the liver that enable them to restore
function following A TN if the initiating insult is not overwhelming. The recovery phase
is characterized by increased urine output, increased GFR, and a decline in SCr and BUN.
Interestingly, most patients who survive A TN recover full renal function with little
evidence of dead tubular tissue, demonstrating the regenerative capacity of the kidney
[21].

RPTC Cell Death in ATN. Epithelial cell death can occur via necrosis and/or apoptosis
and both are involved in the pathophysiology of ATN [24].

A TP levels during and

following injury is a major determinant of the type of cell death that ensues [25].
Sufficient A TP levels are required to initiate and execute apoptosis and apoptosis is
generally considered an ATP dependent process. For example, an insult that depletes
10

ATP levels acutely in a cell to 15% or less will induce necrotic cell death, while cell
injury with less A TP depletion usually results in apoptosis [25]. Apoptosis and necrosis
have significant different effects on surrounding cells and tissues and these differences
may be very important in the progression of many disease processes. Apoptosis, the
more organized form of cell death, is thought to protect surrounding tissues from nonspecific proteolytic degradation while signaling to neighboring injured cells to carry out
the same process. It is also important to note that some types of cell death display
combinations of necrotic and apoptotic characteristics [26].

Necrosis. Necrosis is characterized by loss of plasma membrane integrity and release of
intracellular contents. The intracellular contents themselves contain activated proteolytic
enzymes which damage neighboring cells while resulting in the robust activation of
immune cells which can lead to inflammation and further disruption of neighboring
tissues [27]. Rapid ATP depletion is a major trigger of necrotic cell death in the kidney.
ATP depletion impairs ion transporters, especially the Na+/K+-ATPase and Ca2+-ATPase,
leading to increased cytosolic concentrations of Na+ and Ca2+ [28].

The increased

cytosolic N a+ has two major impacts that facilitate the progression of necrotic cell death.
Initially, the Na+ drives the osmotic movement of water into the cell causing swelling.
Additionally, the intracellular Na+ inhibits the Na+/Ca2+ exchanger leading to further
increased cytosolic Ca2+, which has several deleterious effects on the cell. Ca2+ activates
cytosolic calpains, mediating the loss of cell membrane integrity by cleaving cytoskeletal
proteins which support the plasma membrane [29].
buffered by active mitochondria.

Increased cytosolic Ca2+ is also

Ca2+ sequestration promotes the opening of a
11

proteinaceous pore called the mitochondrial permeability transition (MPT) pore, leading
to further ATP

deph:~tion

[30]. Late in necrotic cell death,

cr and water influx facilitate

opening of a glycine-sensitive plasma membrane pore, the "death channel", which is
porous to macromolecules up to 145 kDa, leads to membrane rupture [31-32].

Apoptosis. Apoptosis is a major contributor to cell death following ischemic and toxic
insults [20, 24]. Apoptosis is an ATP-dependent process that is highly regulated and
involves several signaling pathways that results in the organized cell death.

During

apoptosis, cells maintain plasma membrane integrity and results in cell shrinkage rather
than swelling (swelling is a characteristic finding of necrotic cell death). Extemalization
of phosphatidylserine in the setting of preserved plasma membrane integrity signals
phagocytic cells such as macrophages to migrate towards and engulf injured cells
undergoing apoptotic cell death. The apoptosis may be initiated by both extracellular
stimuli and intracellular signals. Interestingly, while rapid and severe A TP depletion is a
hallmark of necrotic cell death, GTP (guanosine triphosphate) depletion is a major trigger
for apoptotic cell death in the kidney [33].

Extracellular-mediated (extrinsic) apoptosis

IS

initiated by the binding of signaling

ligands to receptors on the plasma membrane, which results in the activation of very
organized signaling cascades.

For example, tumor necrosis factor (TNF)-related

apoptosis-inducing ligand (TRAIL), Fas, and TNF receptor 1 (TNFR1) ligand binding
results in receptor aggregation on the plasma membrane, initiating the formation of the
death-inducing signaling complex (DISC)

The DISC is comprised of activated and
12

aggregated receptors, the Fas-associated death domain (F ADD), and procaspase 8 and its
formation results in procaspase 8 cleavage to caspase 8.

Caspases are a family of

cysteine proteases that play a role in the initation and execution of apoptotic cell death.
Caspase 8 directly cleaves and activates procaspses 3, 6, and 7 (executioner caspases). In
the proximal tubule, death receptors are expressed and up-regulated after injury [34]
representing one mechanism of RPTC apoptosis during ARF.

Additionally, mice

lacking TNFRI exhibit less apoptotic cell death and decreased kidney dysfunction
following a toxic insult.

Opening

of the

mitochondrial

permeability

transition

(MPT)

pore

[30]

or

permeablization of the outer mitochondrial membrane by members of the BCL-2 family
or other mechanisms [35] releases cytochrome c and other factors that facilitate
apoptosis. When cytochrome c is released from the mitochondria it interacts with Apaf-l
and procaspase-9 to form the apoptosome. The apoptosome, if ATP is present, activates
caspase-9 which cleaves and activates procaspase-3.

Permeablization of the outer

mitochondrial membrane also releases Smac/Diablo, Endonuclease G and apoptosis
inducing factor (AIF). Smac/Diablo releases causes apoptosis by inhibiting inhibitor of
apoptosis proteins (lAPs).

lAPs prevent caspase cleavage and activation [36].

Endonuclease G and AIF participate in DNA degradation associated with apoptosis [36].
Interestingly, the kidneys of mice lacking cyclophillin D, a critical component of the
MPT pore, are protected from ischemia-reperfusion injury. Additionally, proapoptotic
members of the BCL-2 family including BID and BAX translocate to mitochondria and
form pores leading to release of apoptotic mediators in models of AKI, while
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overexpression of antiapototic members such as BCL-xL prevents the release of these
mediators, prevents apoptosis, and preserves kidney function following kidney injury.

ROS. Reactive oxygen species are a major component of many disease processes and
mediate injury and response to injury during ATN [20-21]. ROS is the byproduct of
several cellular processes (ie. the incomplete reduction of O2 in mitochondria,
inflammatory cell activation, and drug and toxicant metabolism) [20]. Superoxide and
hydrogen peroxide (H20 2) are important oxidant molecules that are produced by
mitochondria under normal conditions and in greater quantities upon reperfusion or in
mitochondria damaged by toxicants [37].

Increased cytosolic Ca2+ also leads to

superoxide production by activation of proteases which cleave xanthine dehydrogenase to
yield xanthine oxidase [38]. Superoxide dismutase is a major intracellular antioxidant
enzyme that metabolizes superoxide to H202. H20 2 can then be reduced to water by
catalase or it can be converted to the damaging HO' radical in the presence of ferrous iron
(Fe2+) or cuprous ions. HO' radicals are produced in the kidney shortly after reperfusion
in experimental models of ARF [39-40]. Finally, peroxynitrite, produced from the
reaction of superoxide with nitrous oxide, is also reported to contribute to the pathology
associated with ischemic ARF [41].

ROS damage cellular proteins, DNA and lipids.

Protein oxidation is elevated after

ischemia and reperfusion in the rat kidney and the increase is blocked by the antioxidant
n-acetylcysteine [38]. ROS, especially H202 are implicated in DNA strand breaks which
can induce cells to undergo apoptosis [20].
14

Lipid peroxidation describes the chain

reaction initiated when a free radical abstracts hydrogen from an unsaturated fatty acid
linked to a phospholipid inside a cellular membrane.

If it is not stopped, lipid

peroxidation can potentially destroy an organelle or cell membrane. Lipid peroxidation
of cell and organelle membranes increases membrane rigidity and permeability to ions
[20-21].

Furthermore, ROS-mediated lipid oxidation in the mitochondrial inner

membrane inhibits the function of the electron transport chain [42]. End products of lipid
peroxidation such as 4-hydroxy-2,3-nonenal have biological actions including increasing
passive Ca2+ permeability in biological membranes [43]. In summary~ ROS damage
various intracellular targets and lipid peroxidation inhibits membrane structure and
function, impairs mitochondrial function and leads to Ca2+ influx.

Ca 2+ Regulation. Ca2 + acts as a universal second messenger and regulates numerous
cellular functions including metabolism, motility, and transport [44]. Loss of Ca2+
homeostasis is critical to many disease processes and is a major component of cell death
pathways including necrosis,

apoptosis,

and

autophagy

[45-51]

(Figure

1-4).

Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular
Ca2+and its disruption often initiates the deleterious cascade of events leading to cell
death and dysfunction [48-54]. Release of the ER Ca2+ stores is a key trigger for necrotic
cell death in renal cells [53].

Thapsigargin inhibits the ER Ca2+-ATPase (SERCA)

causing release of ER Ca2+ and in the presence of A TP the cell can pump out the excess
cytosolic Ca2+, effectively depleting the ER Ca2+ store. Harriman et al. (2002) showed
that thapsigargin exposure prior to A TP depletion blocked calpain activation and necrotic
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cell death, establishing the importance of this intracellular pool of Ca2+ in the death of
renal epithelial cells [53].
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Exchanger

Ca 2+ ATPase

®
Ca2+ --+....,....

/necrosis
apoptosi

Voltage
Dependent
Channel

t

cyt c
AIF

o

SERCA

ER

Figure 1-4. Schematic of the role of Ca2+ in renal cell death. 1. Cytosolic Ca2+ is
regulated by numerous mechanisms and organelles inside renal cells. 2. Endoplasmic
reticulum Ca2+-ATPase (SERCA) pumps on the ER membrane pump Ca2+ into the lumen
of the ER to buffer cytosolic levels participate in signaling. 3. During injury cytosolic
Ca2+ concentrations exceed 400-500 nM and mitochondria begin to actively sequester
Ca2+. This causes opening of the mitochondrial permeability transition (MPT) pore
leading to mitochondrial swelling and inhibition of A TP synthesis. Mitochondrial
swelling facilitates the release of cytochrome c (cyt c), apoptosis inducing factor (AIF),
smac/diablo from the intermembrane space of mitochondria which in the presence of
ATP cause the cell to undergo apoptosis. If MPT has spread to a sufficient proportion of
mitochondria and cellular A TP becomes depleted the cell will undergo necrosis. 4. A
rise in cytosolic Ca2+ also activates cytosolic calpain, a protease which mediates
apoptosis and necrosis. 5. Membrane bound Ca2+ efflux pumps use the Na+ gradient and
ATP to remove Ca2+ from the cytosol. 6. Ca2+ enters from the extracellular space
through a voltage gated channel. Adopted with permission from Kinsey OR 2007.
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Mitochondria have a large capacity for Ca2+, which is shuttled into the matrix by a
ruthenium red (RR)-sensitive channel called the Ca2+ uniporter [55].

In the kidney,

substantial mitochondrial Ca2+ uptake occurs after cytosolic concentrations reach 400 nM
or greater which is usually only seen during cell injury [56]. There is a negative
correlation between the matrix Ca2+ concentration and oxidative phosphorylation and
ATP production [21]. Furthermore, mitochondrial Ca2+ accumulation favors the opening
of the MPT pore, which depolarizes the inner membrane and compounds the injury with
futile ATP hydrolysis by F(l )F(O)-ATP synthase in reverse mode in an attempt to restore
mitochondrial membrane potential [57]. In summary, Ca2+ is an important signal from
the ER and to the mitochondria during renal cell death.

Role of Phospholipase A2 in AKI.

Phospholipase A2 (PLA2) activity has been

implicated in the progression of ischemialreperfusion-induced failure of the heart, brain,
and kidney.

Ischemia has been shown to activate PLA2 leading to membrane

degradation and lysophospholipid accumulation, which impair membrane function and
integrity and lead to cell death [58-61].

Additionally, secretory and Ca2+-dependent

phospholipase A2 inhibitors prevented cell death in vivo after heart [62] and brain [63]
ischemialreperfusion (I/R). The addition of purified bee or snake venom secretory PLA2
to hypoxic rat renal proximal tubules caused degradation of phospholipids which
increased as ATP levels declined and was mitigated by addition of ATP [64]. While cell
death was not measured, PLA2 addition inhibited uncoupled respiration and decreased
intracellular K+ content during hypoxia [64]. Cytosolic Ca2+-independent PLA2 (iPLA2)
17

is reportedly activated by hypoxia in rabbit renal proximal tubule sections, while no
change was observed in membrane-bound iPLA2 activity in this model during hypoxia
[65]. Inhibition of cytosolic iPLA2 activity inhibited hypoxia-induced arachidonic acid
generation and lactate dehydrogenase release [65].

In summary, many studies have

implicated PLA2-mediated membrane degradation in the cell injury induced by I/R in
several organs including the kidney.
However, in different studies, addition of pancreatic PLA2 or venom PLA2 to hypoxic rat
renal proximal tubule segments prevented cell death even in the presence of ATP
depletion [66-67]. The protective effect of PLA2 in these studies is hypothesized to be
due to a negative feedback effect of unsaturated free fatty acids on endogenous PLA2
[21]. Additionally, studies from our laboratory have shown that membrane-associated

iPLA2 inhibition in primary cultures of rabbit RPTC potentiates oxidant-induced lipid
peroxidation and necrosis [68].

In summary, the different isoforms of PLA2 may have

different roles in ARF and the role of iPLA2 in ARF may depend on its intracellular
localization.

Phospholipids. The major structural components of cell and organelle membranes are

phospholipids (PLs).

There are hundreds of different types of phospholipids in

mammalian membranes which can vary in the fatty acids linked at the sn-l and sn-2
positions, the type of linkage between the glycerol backbone and the sn-l fatty acid, and
the polar head group [69] (Figure 1-5). In addition to providing a barrier between the
extra- and intracellular space, PLs playa vital role in cell signaling.

For example,

stimulation of G-protein coupled receptors (GPCRs) activates phospholipase C (PLC)
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which cleaves the PL phosphatidylinositol-4,5-bisphosphate in the cell membrane,
generating inositol-triphosphate and diacylglycerol (DAG). These two molecules play
key roles in the intracellular signaling of GPCR activation by triggering the release of ER
Ca2+ and activating PKC, respectively. PLs are precursors of platelet activating factor
(PAF) that interacts with a GPCR to regulate cardiac function and renal blood flow and
may mediate atherogenesis [70-71]. In summary, phospholipids are a class of molecules
with an extremely large number of members, are required as a major structural
component of cell and organelle membranes and are used to transmit signals inside the
cell and from one cell to another.
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Figure 1-5. Glycerophospholipids and site of PLA2 hydrolysis. PLA2 enzymes
catalyze the cleavage of the sn-2 ester bond of glycerophospholipids (*). Fatty acids of
14 to 24 carbons in length, containing 0 to 6 double bonds are esterified to the glycerol
backbone at the sn-2 position. At the sn-1 position, fatty acids can be linked to the
glycerol backbone by an ester bond (shown) and referred to as a phosphatidyl- or diacylphospholipid or by a vinyl ether bond and referred to as a plasmenyl- phospholipid.
Phospholipids with an ether linkage at the sn-1 are termed plasmanyl- phospholipids.

Fatty acids. Phospholipids are a reservoir of fatty acids, the structural building blocks of
phospholipids and another very important component of cell signaling. Arachidonic acid
(AA, a fatty acid with 20 carbons and 4 double bonds, denoted 20:4) is the most well

known and extensively studied fatty acid although many other fatty acids have biological
activity. AA is metabolized by: cyclooxygenases to prostaglandins and thromboxane A 2;
lipoxygenases to leukotrienes and cytochrome p450 enzymes to several other oxidized
signaling molecules [72]. Other fatty acids, such as linoleic, oleic, and palmitic acids are
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in high abundance in the kidney and are thought to play a major role in phospholipid
structure and function and cell signaling (Figure 1-6) [73].

# of
Carbons:
Double
Bonds
14:0
15:0
16:0
16: 1
17:0
18:0
18:1
18:2
18:3
20:1
20:4
20:5
22:5
22:6

Trivial Name

Myristic
n.a.
Palmitic
Palmitoleic
Margaric
Stearic
Oleic
Linoleic
Linolenic
Gondoic
Arachidonic
n.a.
n.a.
n.a.

Systematic
Name

Weight
Percentage in
Kidney*

tetradecanoic
pentadecanoic
hexadecanoic
hexadecenoic
heptadecanoic
octadecanoic
octadecaenoic
octadecadienoic
octadecatrienoic
.
.
elcosenOlC
eicosatetraenoic
eicosapentaenoic
docosapentaenoic
docosahexaenoic

<1
<1
19.2
2.4
<1
13.4
21.9
24.4
<1
<1
12.1
<1
1.7
<1

Figure 1-6. Common fatty acid components of mammalian kidney phospholipids.
*Mean weight percentage of each fatty acid in lipids of kidney from D. C. Rule et aI.,
1994 [73]. Most abundant fatty acids are in bold. n.a. - fatty acids without established
trivial names.

Lipid Peroxidation. ROS generation is a major component of ischemialreperfusion and
drug and toxicant injury. Major targets of ROS are cell and organelle membrane
phospholipids [74]. The initiation step of lipid peroxidation involves the abstraction of a
21

hydrogen atom from the methylene carbon of a fatty acid and therefore fatty acids with
more double bonds are more vulnerable to the initiation of lipid peroxidation [75]. These
fatty acid species are usually polyunsaturated fatty acids (PUFAs). Abstraction of the
hydrogen atom from PUF As forms a pentadienyl radical, which in aerobic conditions
reacts with oxygen to form a peroxyl radical. The resulting peroxyl radical is capable of
abstracting a hydrogen atom from adjacent fatty acids, thus propagating the lipid
peroxidation and potentially producing several lipid hydroperoxides [76]. This chain of
events can be terminated by the removal of the reactive lipid from the site of reaction or a
chain-breaking antioxidant (Figure 1-7) [75-77].
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Figure 1-7. Schematic representation of free radical attack on membrane
phospholipids. (A) Initiation of lipid peroxidation. The free radical (X', normally a
hydroxyl radical) abstracts a proton from an sn-2 unsaturated fatty acid linked to the
glycerol backbone of a membrane phospholipid, forming a pentadienyl radical (a).
Oxygenation forms a peroxyl radical and a conjugated diene, (b). (B) Propagation of lipid
peroxidation. The peroxyl radical abstracts a proton from a methylene of a neighboring
polyunsaturated fatty acid forming a new pentadienyl radical that react with oxygen to
form another peroxyl radical and this pattern continues until the oxidized fatty acids are
removed from the membrane or react with a chain terminating molecule such as utocpherol. Adapted from [78-79]
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In mammalian tissues, PUF As are predominantly esterified at the sn-2 position of PLs
[80]. It has been proposed that phospholipases playa role in membrane remodeling and
repair during oxidant stress by cleaving oxidized and/or unsaturated fatty acids from the
membrane, preventing the initiation and propagation of lipid peroxidation, and allowing
for the incorporation of unoxidized fatty acids [74]. ER and mitochondria are the major
sites of reactive oxygen species (ROS) production and the presence of iPLA2y in
mitochondria and ER of rabbit RPTC makes it a likely candidate for a role in membrane
repair and remodeling. The most probable mechanism by which these enzymes prevent
or repair lipid peroxidation is through the cleavage and removal of oxidized fatty acids
from the membrane [81] The liberated oxidized free fatty acid can then be reduced by
cytosolic glutathione peroxidase (GPx) and the lysophospholipid reacylated by a CoAdependent acyltransferase to reform a non-oxidized phospholipid and preserve membrane
integrity [82]. In vitro analyses in non-cell based systems have demonstrated that, in
concert with GPx, PLA2 enzymes are capable of performing this protective repair
function [83-85]. Thus far, the PLA2 isoform(s) involved in this important cell survival
function has not been determined in vivo or in an intact cell model. However, recent
studies from our laboratory have demonstrated that inhibition of membrane-associated
iPLA2 activity in RPTC potentiated oxidant-induced lipid peroxidation [68], but thus far
the tools necessary to identify this isoform have not been available. Furthermore, the role
of this lipid peroxidation repair pathway in prevention of or hastening recovery from
ARF has not been addressed.
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Review of Phospholipase A2 Biology

PLA2 Overview. Phospholipase A2 (PLA2) enzymes catalyze the hydrolysis of fatty
acids at the sn-2 position of glycerophospholipids resulting in the production of a free
fatty acid and a lysophospholipid [86]. Free fatty acids and their metabolites are
biologically active in such processes as inflammation, cell signaling, and cell death.
Interestingly, Polyunsaturaed fatty acids (PUFAs) are predominately esterified at the sn-2
position of phospholipids [80]. Arachidonic acid, for example, is metabolized to
prostaglandins, prostacyclins, thromboxanes and leukotrienes, all of which playa role in
inflammatory responses and cell signaling [87]. The resulting lysophospholipids serve as
substrates for the re-esterification of free fatty acids by eoA-dependent acyltransferases
and are also cell signaling molecules [82]. The deacylation and reacylation of
phospholipids is termed "The Lands Cycle" and may be involved in membrane
remodeling and the maintenance of membrane homeostasis under physiological and
pathological conditions.

However, there are limited studies investigating this

phenomenon in cellular systems [88].
PLA2 enzymes are classified according to the homology of their nucleotide sequences
into 14 groups designated groups I-XIV [86] or according to a historical classification
based on functional characteristics into 4 groups: secretory PLA2 (sPLA2), cytosolic
PLA2 (cPLA2), lipoprotein associated PLA2s platelet-activating factor acetylhydrolases,
and Ca2+-independent PLA2 (iPLA2) [89].
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Calcium-independent phospholipase A2Y (iPLA2Y)

is one of seven Ca2+-independent

PLA2 enzymes [81] (Figure 1-8). iPLA2 enzymes do not require Ca2+ for activity or
translocation, range in size from 29 to 85 kDa, have an ATP-binding motif and lipase
sites, and, with the exception of certain splice variants of iPLA2B, are membraneassociated [90]. The first mammalian iPLA2 described was iPLA2 J3 [91] (Group VIA
PLA2) and much is now known about this enzyme including regulation of activity [92]
and its physiological and pathological roles (see below). iPLA28 (Group VIC PLA2) is
also called the neuropathy target esterase and is found predominately in neurons [93].
Three newer members, iPLA2E, sand 11 (Groups VID, VIE and VIF) possess modest
classical PLA2 activity (sn-2 hydrolysis of phospholipids) and are efficient triglyceride
lipases and acylglycerol transacylases [94]. Mancuso et al. and Tanaka et al. identified
iPLA2y in non-mammalian Sf-9 (insect) and COS-7 (bacterial) cells, respectively in 2000
[95-96]. In 2002, our laboratory reported the expression of an 85-kDa mammalian iPLA2
selective for plasmalogen phospholipids and with an inhibitor profile not consistent with
iPLA2B in the ER of rabbit RPTC [68]. We identified the ER iPLA2 as iPLA2y; showed
its presence in different species including humans; confirmed its activity in various
tissues including the brain, heart, and kidney; and excluded the presence of iPLA2B[97].
More recent studies identified iPLA2y in the mitochondria of rabbit renal cortex and
RPTC [98].
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Calcium-Independent PLA2 Isoforms
Other Names
Historical
Group
PNPLA
Number
Classification
Number
B.a.
VIA
VIB
VIC
''II)

iPLA2a (alpha)
iPLA2f} (beta)
iPLAty (gamma)
iPLA20 (delta)
iPLA28 (epsilon)
iPLA2S (zeta)
iPLA21l (et~)

o.a.
9

8
6
3
2

VIE
VIF

4

patatin
PLAlG6
iPLA2-2
neuropathy target esterase
adiponutrin
TTS-2.2
GS2

Figure 1-8 Different naming systems for iPLA2 • Commonly used names for the
members of the iPLA2 family. Historical classifications and group numbers have been
reviewed [81]. Human iPLA2 genes were named patatin-like PLA2 (PNPLA) by Wilson
et al. (2006) and each assigned a number. Other names used in the literature to identify
each iPLA2 isoform are also listed. n.a. - not assigned.

iPLA2 p. iPLA2P is predominately expressed as a cytosolic protein and is regulated by
several different mechanisms. The peptide sequence encodes ankyrin repeats [99] which
participate in protein-protein oligomerization interactions of different iPLA2P splice
variants that regulate catalytic activity [100].

The stability and activity of purified

iPLA2P are increased in the presence of ATP [101] and activity is inhibited by
calmodulin binding [102].

Caspase-mediated iPLA2P activation results in increased free

fatty acid release and generates lysophosphatidylcholine, a novel chemotactic signal to
attract phagocytes toward apoptotic cells [103].

iPLA2P is reported to mediate pancreatic insulin secretion [104], phospholipid
remodeling

[105],

st ore

operat ed

Ca2+
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entry

[106],

and

ischemia

induced

arrythmyogenesis [107].

Ramanadham et al. (2003) demonstrated that overexpression

of iPLA2~ in pancreatic insulinoma cells amplifies glucose-stimulated insulin secretion
and this effect is inhibited by the irreversible mechanism based iPLA2 inhibitor
bromoenollactone (BEL) [104]. In a human lymphoma cell line (U937), BEL blocked
the production of lysophospholipid acceptors for AA, and the incorporation of AA into
membrane phospholipids [105]. In a follow-up study, overexpression of iPLA2(3
accelerated AA incorporation into U937 cell membrane PLs, confirming the role of
iPLA2(3 in phospholipid remodeling [108]. In summary, iPLA2(3 activity is associated
with many physiological functions.

Taking advantage of the fact that mice express very little iPLA2(3 activity in the heart,
Mancuso et al. (2003) generated an iPLA2(3 transgenic mouse and utilized isolated
perfused hearts from wild type and transgenic animals to investigate the role of iPLA2~
during IIR. Transgenic mice were no different than wild type mice in terms of body
weight, heart weight or cardiac function as measured by echocardiograph, prior to
ischemia [107]. After I1R, transgenic hearts had greatly increased amounts of FF As and
lysophospholipids (products of PLA2 activity known to cause electrical abnormalities in
excitable cells) and arrhythmias occurred in the transgenic hearts but not wild type [107].
Pretreatment with BEL completely blocked FF A and lysoPL accumulation and
arrhythmias in the transgenic mice [107] suggesting that iPLA2(3 inhibition may lead to
clinical benefit after myocardial infarction.

In summary, iPLA2(3 has been studied

extensively and demonstrated to play important roles in physiology and pathology.
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iPLA2y. In 2000, two independent laboratories identified a novel iPLA2, iPLA2Y (Group
VIB PLA2), which appeared to be constitutively membrane bound and possesses a Cterminal SKL peroxisomal targeting sequence [95-96]. Since then, several studies have
revealed that iPLA2y is subject to transcriptional and translational regulation, is targeted
to various intracellular organelles and is implicated in physiology and pathophysiology of
different organs [95, 109-110]. Importantly, rabbit iPLA2Y shares approximately 88%
amino acid sequence homology with human iPLA2y and the sequence of its catalytic
domain shares 100% homology, suggesting similar lipase activities [97-98].

Expression of iPLA2y. Based on segments of homology, between a predicted protein
encoded on the long arm of chromosome 7 discovered during the Human Genome
Project, and the previously identified members of the iPLA2 family, Mancuso et al.
(2000) determined the full-length mRNA sequence of iPLA2y.

In a separate laboratory,

the C-terminal DNA sequence of iPLA2~ was compared to EST databases in an effort to
discover a novel iPLA2 (termed iPLA2-2) [96]. Both iPLA2 enzymes had identical 782
amino acid sequences and are homologous to iPLA2a and

iPLA2~

only through the AIP

binding and GXSTG lipase motifs. Whether expressed in insect or mammalian cells,
iPLA2y localized to crude membrane fractions and was not detected in cytosol [95-96].
In COS-7 cells (kidney fibroblast cell line), transfection with full-length iPLA2y cDNA
resulted in the expression of the expected 88 kDa protein [96]. In contrast, the full-length
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cDNA in a rabbit reticulocyte lysate protein expression system or in Sf9 insect cells
produced 77 and 63 kDa protein products [95]. These protein products correspond to
translation initiation at downstream in-frame methionine residues on iPLA2Y mRNA [95,
110].

Mancuso et al. (2004) performed extensive experiments designed to determine how the
expression of different sized iPLA2Y isoforms is regulated at the transcriptional and posttranscriptional levels.

They discovered that iPLA2Y expression is repressed by

transcriptional regulatory elements in the coding regions of iPLA2y between the 88 kDa
and 63 kDa start sites [110].

Using electrophoretic mobility shift analyses, the binding

of unidentified nuclear proteins to iPLA2y DNA was demonstrated which may also
regulate transcription [110]. Initiation of translation at in-frame methionines of different
splice variants potentially results in the expression of 92, 88, 77, 74 and 63 kDa isoforms
and an inactive 33 kDa isoform ofiPLA2y [110]. In summary, multiple forms ofiPLA2y
exist and the expression of iPLA2y is subj ect to rigorous control at many levels and is still
not completely understood.

Regulation of iPLAiY Activity. Little is known about the regulation of iPLA2y activity.
Initial analysis of the protein revealed numerous potential phosphorylation sites including
protein kinase A, PKC and mitogen-activated protein kinase consensus sequences [96].
Phosphorylation of iPLA2y at specific amino acids has not been unambiguously
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demonstrated, but several experiments from different laboratories support the hypothesis
that iPLA2y activity is regulated by phosphorylation. First, separation of heart proteins
from a heart-specific iPLA2y transgenic mouse, by two dimensional gel electrophoresis,
revealed that each molecular weight isoform of iPLA2y separated into multiple distinct
spots with different isoelectric points (potentially representing different patterns of
phosphorylation) [109]. Furthermore, isolated micro somes from rabbit heart and kidney
cortex, treated with phorbol 12-myristate 13-acetate (PMA, an activator of PKC),
demonstrated increased iPLA2 activity [111-112]. Further studies revealed renal cortex
mitochondrial iPLA2y activity is enhanced in the presence of A TP and blocked by PKC
inhibitor (PKCE inhibitor VI-2) [98, 113].

Extensive oxidative stress negatively regulates iPLA2 activity in rabbit kidney cortex
[114] and rat myocyte micro somes [115].

tert-Butyl hydroperoxide (TBHP)-induced

inactivation of kidney microsomal iPLA2 was reversible by adding the reducing agent
dithiothreitol (DTT) suggesting that oxidants target protein thiols on iPLA2 [114].
However, non-lethal oxidant stress increased iPLA2Y expression and activity [116].

A calcium ionophore, A23187, was shown to activate iPLA2Y when overexpressed in

HEK293 cells [117] suggesting that iPLA2y activity may be indirectly regulated by
increased intracellular Ca2+ concentrations.

ER-iPLA2 in rat ventricular myocytes is

activated by the inflammatory cytokine IL-1 J3 in a BEL-sensitive manner, which may
indicate that iPLA2y plays a role in stimulus-induced AA generation and inflammation
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[118]. Murakami et al. (2005) also reported that AA and oleic acid release was greatly
increased in iPLA2Y overexpressing cells when exposed to fetal calf serum and IL1B. Thrombin receptor activation, by thrombin or analogs thereof, also activates
microsomal iPLA2 in the heart leading to the production of arrhythmogenic lysophosphatidylcholine and FFAs [119]. The activation of iPLA2Y by cytosolic Ca2+,
inflammatory cytokines and thrombin demonstrate that iPLA2Y is regulated by diverse
mechanisms and establish iPLA2y as a potential drug target for treatment of inflammatory
diseases as well as prevention of post-ischemic arrhythmia in the heart. The regulation of
iPLA2y in the kidney has not been elucidated.

iPLA2¥ Pharmacological Inhibition. Predominate iPLA2 isoforms may be distinguished

by their activity profiles in response to pharmacological inhibitors. These differential
inhibitor profiles have been used to identify the presence of the enzymes in subcellular
fractions and are used to investigate the roles of phospholipases in both physiological and
pathological processes. Methyl arachidonyl fluorophosphonate (MAFP) inhibits cPLAiY
and cytosolic iPLA2P, but not iPLA2y [68, 112]. Racemic BEL inhibits both iPLA2P and
iPLA2Y, but the enantiomers of BEL are differentially selective for the two enzymes.
iPLA2y is more sensitive to R-BEL than S-BEL, whereas iPLA2P is more sensitive to SBEL than R-BEL [68,97, 112-113].
iPLA2Y is sensitive to the pharmacological inhibitor racemic BEL at low micromolar
concentrations [95], similar to iPLA2P [120]. However, other pharmacolo"gical inhibitors,
arachidonyl

trifl uoromethy lketone

(AACOCF 3)
32

and

methylarachidonyl

fluorophosphonate (MAFP), which inhibit iPLA2J3 at low micromolar concentrations
[121-122] do not inhibit microsomal iPLA2 [68, 123]. Furthermore, Jenkins et al. (2002)
demonstrated that separation of racemic BEL into the R- and S-enantiomers provides a
mechanism to discriminate between iPLA2¥ and iPLA2J3 activity (i.e. iPLA2¥ is 10-fold
more sensitive to R-BEL than S-BEL and iPLA2J3 is 10-fold more sensitive to S-BEL
than R-BEL) (Figure 1-9).

The use of different iPLA2 inhibitors to confirm the

participation of iPLA2Y in various biological processes has recently been used by several
investigators [124-125].
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Figure 1-9. Differential effect of Rand S enantiomers of BEL on microsomal iPLA2
activity in RPTC, ventricular myocyte microsomes or in microsomes isolated from
HEK293 cells. RPTC (A) were treated for 30 minutes with either (acetonitrile), R-BEL
or S-BEL. Rabbit cardiomyocyte (B) and HEK293 (C) microsomes were isolated and
incubated with solvent control (acetonitrile), R -BEL or S-BEL for 10 minutes prior to
activity assays. iPLA2 activity was measured using plasmenylcholine (16:0, [3 H] 18: 1)
or substrates in the presence of 4mM EGTA. Values are means + SEM of at least 3
separate experiments. Means with different subscripts are significantly different from
each other, P<0.05 . Adopted from Kinsey "et. a12007.

iPLA2¥ Substrate Specificity.

The initial characterization of iPLA2¥ substrate

specificity demonstrated that membrane fractions from Sf9 insect cells expressing iPLA2y
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cleaved phosphatidylcholine (PC) with unsaturated fatty acids at the sn-2 position but did
not cleave palmitic acid (16:0) from the sn-2 position [95]. Of the unsaturated fatty acids
at the sn-2 position tested, iPLA2Y activity was highest against AA containing PC.
iPLA2Y was also slightly more active against plasmenylcholine (PlasC) with sn-2 oleic
acid compared to oleic acid containing PC [95]. The authors of this study cautioned that
differences observed in the activity of a membrane bound enzyme measured using
exogenous substrates may only reflect the rate of membrane incorporation of different
types of PLs [95].

Several subsequent studies have further examined the activity of

iPLA2y against different PL species using different methodologies.
The same group later overexpressed a His-tagged iPLA2Y and was able to purify a soluble
63 kDa isoform from Sf9 cytosol [126]. Interestingly, the soluble iPLA2y cleaved sn-2
oleic acid more rapidly than sn-2 AA from PC with palmitic acid at the sn-l position.
Using electro spray ionization/mass spectrometry (ESI/MS) and tandem MS it was
determined that soluble iPLA2Y would preferentially cleave the sn-1 palmitic acid from
PC, generating 2-arachidonyllysoPC [126]. This finding was unexpected, but potentially
significant, since 2-arachidonyl lysoPC is a key signaling molecule with the potential to
be

metabolized

to

prostaglandins,

leukotrienes

or

2-arachidonylglycerol

(an

endocannabinoid). Soluble iPLA2Y also displayed significant lysophospholipase activity
against I-palmitoyl lysoPC [126]. While these studies attempt to identify the activity of
soluble iPLA2y, the substrate specificity of soluble iPLA2y may be very different than the
isoforms of iPLA2y that are constitutively membrane bound.

In intact renal cortex

mitochondria, our laboratory showed iPLA2Y displays preferential activity against
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plasmenylcholine with AA in the sn-2 position over oleic acid [98] and further studies
revealed a preference for AA in both stressed and basal conditions in renal cortical
mitochondria [127].

The activity of microsomal iPLA2 in the heart using different radiolabeled PL substrates
and reverse-phase HPLC quantitation of PL abundances has also been studied. Rabbit
ventricular myocyte iPLA2 preferred PlasC 16:0;18:1 over PC 16:0;18:1 and liberated
significantly more sn-2 AA than oleic acid from synthetic PC, PlasC and
plasmanylcholine PLs [123].

Furthermore, thrombin stimulation of rabbit ventricular

myocytes caused a BEL-sensitive decrease in abundance of sn-2 AA containing PlasC
and PlasE and no change in PC or PE containing sn-2 AA [128].

In the kidney,

microsomal iPLA2 also prefers PlasC over PC PLs with oleic acid at the sn-2 position,
but the AA and polar head group selectivity has not been determined [68].

In summary, different substrate specificities of iPLA2Y have been reported which may
reflect differences in techniques used for measurement (e.g. radiolabeled synthetic
substrates vs. ESIIMS of changes in cellular phospholipid abundances), differences in the
isoform responsible for activity (e.g. cytosolic His-tagged vs. overexpressed membranebound vs. native microsomal iPLA2Y) or differences in the regulatory mechanisms in
place in the different cellular extracts used for measurement (e.g. phosphorylation state of
iPLA2y, presence of Ca2+ or ROS). Overall, when acting as a classical PLA2, iPLA2Y
preferentially cleaves AA from the sn-2 position of vinyl ether containing PLs
(plasmalogens ).
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Intracellular Localization of iPLA2y. The localization of iPLA2y to crude membrane
fractions when overexpressed in Sf9 and COS-7 cells and the presence of a C-terminal
SKL peptide sequence led to speculation that this enzyme was targeted to peroxisomes
[95]. In fact, the first demonstration of native iPLA2¥ expression was the 63 kDa isoform
in purified rat liver peroxisomes [129]. Subsequently, Mancuso et al. (2004) reported
that higher molecular weight isoforms were found in rat heart mitochondria and nuclear
......

fractions.

The mechanism for mitochondrial targeting was determined to be an N-

terminal amino acid sequence present in the 88, 77 and 74 kDa isoforms but absent in the
63 kDa iPLA2¥ [110].

Additionally, cytosolic iPLA2¥ was observed following

overexpression in a transgenic mouse [109] Our laboratory demonstrated the expression
of an iPLA2 activity in the microsomal (ER) fraction of rabbit RPTC that is sensitive to
BEL [68] and Beckett et al. (2006) reported that the majority of human platelet iPLA2
activity is cytosolic and is inhibited by R-BEL, an iPLA2¥ selective pharmacological
inhibitor. A strongly immunoreactive protein of approximately 50 kDa in platelet cytosol
was detected with an anti-iPLA2y antibody [130]. Later, we demonstrated the presence of
iPLA2¥ in renal mitochondria and excluded the presence of iPLA2Pactivity [68, 97-98].
In summary, iPLA2¥ protein and/or activity has been identified in peroxisomes,
mitochondria, nuclei, microsomes and cytosol and its presence in other subcellular
compartments has not been ruled out.

Mitochondrial iPLA2• Ca2+-independent PLA2 activity has been demonstrated in rat
liver mitochondria [131] and in rabbit ventricular myocyte mitochondria [132].
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The

isoform identity of each iPLA2 was hypothesized to be iPLA2P, based on positive
immunoblot analyses with a commercially available iPLA2P antibody and sensitivity of
the activity to racemic BEL [131-132]. In rat liver mitochondria the iPLA2 is supposedly
activated by dissipation of the mitochondrial membrane potential and is hypothesized to
facilitate removal of poorly functioning mitochQndria by destruction of mitochondrial
phospholipids [131]. Prevention ofIlR-induced cardiac infarct in isolated perfused hearts
by BEL was attributed solely to mitochondrial iPLA 2 inhibition and the contribution of
the well-described microsomal iPLA2 in rabbit ventricular myocytes was not taken into
account [132].

Both mitochondrial iPLA2 are localized to membrane fraction of

mitochondria and the rabbit heart iPLA2 was specifically localized to the inner
mitochondrial membrane [132].

Gross and colleagues have demonstrated the presence

of iPLA2y protein in mitochondria from rat heart with an iPLA2Y antibody, but
mitochondrial iPLA2Y activity was not measured [110]. It is possible that both iPLA2
activities described previously in rabbit heart and rat liver are the result of iPLA2y and not
iPLA2P, based on the inhibition profile of these mitochondrial enzymes. These studies
report that AACOCF 3 either does not inhibit mitochondrial iPLA2 activity [131] or has no
effect on ischemia-induced infarct size [132], while racemic BEL potently inhibits both
endpoints in these studies.

The inhibitor sensitivity profile (BEL-sensitive and

AACOCF3-insensitive) matches iPLA2Y and not iPLA2P.

In 2007, Kinsey et. al.

identified iPLA2y in rabbit renal proximal tubules by immunoblot analysis and activity
studies and excluded the presence of iPLA2(3 [98]. Interestingly, pharmacological
inhibition of iPLA2y with BEL potentiated oxidant-induced mitochondrial lipid
38

peroxidation and swelling, but prevented Ca2+-induced mitochondrial permeability
transition (MPT) by preventing arachidonic acid release in isolated mitochondria [98,
113].

Endoplasmic Reticulum iPLA2y Prior to the identification of mitochondrial iPLA2y
most studies did not take into account differential subcellular localization of iPLA2y and
activity was considered either microsomal (ER) or peroxisomal. Additionally, lack of
organelle specific inhibitors of iPLA2Y has made identification of differential function of
iPLA2y within organelle difficult. Therefore studies are limited to isolated organelle to
determine organelle specific activity. Interestingly, pharmacological inhibition of iPLA2y
with the selective inhibitor bromoenollactone (BEL) reduced cisplatin-induced apoptotic
renal proximal tubule cell (RPTC) death and in contrast, iPLA2y inhibition potentiated
oxidant-induced lipid peroxidation and necrotic RPTC death [68, 98]. These data provide
further evidence that iPLA2y may have divergent roles in cell injury and death, which
may be explained by unique roles and functions within subcellular compartments [81].
These data implicate" iPLA2y as a mediator of apoptotic cell death and as a protectant in
oxidant-induced necrotic cell death.

Recent studies in our laboratory used iPLA2y-

specific shRNA to decrease iPLA2y activity and expression in RPTC [116]. While the
loss of mitochondrial iPLA2Y was correlated with decreased mitochondrial uncoupled
respiration,

these

studies

pointed

to

ER-

iPLA2y

in the

lipid peroxidation

repair/prevention pathway because knockdown of ER- iPLA2Y was correlated with
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increased lipid peroxidation [116]. These studies underscore the need of further studies to
elucidate the differential roles of iPLA2y with respect to subcellular localization.
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Figure 1-10. Small hairpin ribonucleic acid (shRNA)-mediated decreases in
mitochondrial and ER- iPLA2y in RPTC. Confluent RPTCs were exposed to either
adenoviral iPLA2y or scramble shRNA and cultured normally for 4 days.
iPLA2y expression was measured by immunoblot analysis (A, B) and iPLA2 activity was
measured (C, D) in mitochondrial (A, C) and ER (B, D) fractions at 24, 48, 72, and 96 h
after exposure. The amount of iPLA2y expression and activity in cells exposed to
iPLA2y shRNA is expressed as means +SEM, percentage of iPLA2y expression and
activity in cells exposed to scramble shRNA for the same amount of time. Insets show
representative immunoblots. Means with different superscripts are significantly different
from each other (P< 0.05, n = 4-5). Note: ER- iPLA2y expression and activity decreases
prior to decreases in mitochondrial-iPLA2yexpresion and activity. From Kinsey et al
[116].
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Figure 1-11. Effects of decreased iPLA2¥ expression on RPTC lipid peroxidation.
The thiobarbituric acid-reactive substances (TBARS) assay was performed in noninfected
(control), scramble shRNA, and iPLA2¥ shRNA adenovirus-treated RPTCs at 24, 48, and
72 h after virus exposure as a measure of cellular lipid peroxidation. Data are presented
as means + SEM, percentage of control TBARS formation. Means with different
superscripts are significantly different from each other (P < 0.05, n=4). Note: lipid
peroxidation occurred at 24 h and correlated with decreases in ER- iPLA2¥ and prior to
decreases in mitochondrial- iPLA2¥ activity and expression. From Kinsey et. al [116].

iPLA2¥ in the Brain. iPLA2¥ has been suggested to play a protective role in the brain
during oxidant stress.

Inhibition of iPLA2¥ prior to oxidant treatment in astrocytes

potentiated oxidant induced cell death[133].

Mice genetically ablated of iPLA2¥

exhibited cognitive dysfunction and cortical tissues exhibited multiple inclusion bodies
following immunohistochemical staining [134-136].

These consequences of genetic

ablation of iPLA2y were attributed to loss of cardiolipin homeostasis, resulting in
mitochondrial dysfunction.
41

mouse

[1
an

mice [1

more

[1
manner

[3

13

.

the heart [138-139]. The toxicity of doxorubicin in the heart is related to increased ROS
production, causing lipid peroxidation in cardiac membranes, and anthracyclines also
prevent the repair of lipid peroxidation by inhibiting microsomal iPLA2 [137]. Similar to
the effects of iPLA2 inhibition on oxidant-induced necrosis in the kidney, BEL
pretreatment significantly potentiated lactate dehydrogenase release from cardiac
myocytes exposed to doxorubicin [139]. Most recently, Mancuso et. al. reported that
mice genetically ablated of iPLA2Y were more vulnerable to cardiac stress (transverse
aortic constriction) [136].

iPLA2¥ in the Kidney. Inhibition of microsomal iPLA2 in RPTC with racemic BEL,
potentiates lipid peroxidation and necrotic cell death induced by diverse oxidants but has
no effect on non-oxidant induced necrosis [68] (Figure 1-10).

Effects of BEL on

glutathione, ATP, GTP and mitochondrial function were ruled out, and BEL-induced
potentiation of oxidant-induced lipid peroxidation was observed well before cell death
was detectable [68] (Figure 1-11). In a subsequent study, treatment ofRPTC with TBHP
resulted in the significant loss (presumably by oxidative damage) of 4 individual PL
species (of 28 total measured), but pretreatment with BEL caused a TBHP-induced loss
of 15 out of28 PLs [114].
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Figure 1-12. Effect of iPLA2 inhibition on necrotic cell death in RPTC. RPTC were
treated with diluent or racemic BEL (5 f.lM) 30 minutes prior to exposure to the oxidants:
TBHP (200 f.lM) for 24 hr; cumene H 2 0 2 (200 f.lM) for 24 hr; menadione (10 f.lM) for 12
hr; duraquinone (400 f.lM) for 24 hr and cisplatin (400 f.lM) for 24 hr, or the non-oxidant,
antimycin A (0.3 f.lM) for 4 hr, and necrotic cell death measured by flow cytometry as the
percent cells positively stained with propidium iodide (PI). From Cummings et. al [68].
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Figure 1-13. Effect of iPLA2 inhibition on lipid peroxidation in RPTC. RPTC were
;( ;+v

treated with diluent or racemic BEL (5 ~M) 30 minutes prior to exposure to TBHP (200
~M), cumene H 2 0 2 (200 ~M), menadione (10 ~M), duraquinone (400 ~M) , cisplatin
(400 ~M) and antimycin A (0.3 ~M) each for 2 hr, and prior to any increase in cell death,
lipid peroxidation (malondialdehyde (MDA) formation) estimated using the
thiobarbituric acid reactive substances assay. From Cummings et. al [68].

In the same RPTC model, inhibition of microsomal iPLA2 blocks non-oxidant mediated
cisplatin (50

~M)-induced

apoptosis (PS extemalization, chromatin condensation and

caspase 3 activity) but not p53 nuclear translocation [112]. In addition, activation of
microsomal iPLA2 with PMA increased cisplatin-induced annexin-V staining and cell
shrinkage [112]. These results suggest that, during cisplatin-induced RPTC apoptosis,
iPLA2 activity regulates caspase activation presumably by an AA-mediated mechanism
[140]. Cisplatin is a widely used chemotherapeutic drug with a major dose-limiting side
effect of renal toxicity.

Similarly, Kinsey et. al showed that mitochondrial

iPLA2y mediates Ca2+-induced mitochondrial
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swelling through a AA-dependent

mechanism [98]. Overall, the role of iPLA2 in RPTC necrosis and apoptosis suggest that
manipulation of this enzyme in the setting of ARF may provide novel therapeutic
possibilities.

iPLA2¥ in Skeletal Muscle.

Mancuso et al reported skeletal muscle lacking the

bioenergetic capacity of Interestingly, Yoda et al. also generated mice null of iPLA2Y and
reported in skeletal muscle, increased lipid peroxidation, the induction of oxidative stress
related proteins, and, similarly to the work of Mancuso et aI., alterations in cardiolipin
content and mitochondrial dysfunction[141]. Skeletal muscle ablated of iPLA2y
displayed atrophy of myofilaments, reduced fiber diameter, and alterations in prostanoid
and phospholipids content. Mancuso et al. reported similarly mitochondrial dysfunction
in iPLA2y -/- mice. Skeletal muscle mitochondria exhibited reduced state 3 respiration
and altered cardiolipin composition. Together, these changes seemingly resulted in mice
insensitive to high fat diet induced weight gain and reduced their exercise endurance
[134, 136, 141].

iPLA2¥ in Other Tissues. In the first demonstration of native iPLA2y expression, Yang
et ai. (2003) showed that hepatic peroxisomes possess a 63 kDa protein immunoreactive
to an anti-iPLA2y antibody. Based on the phospholipid content of peroxisomes from rat
liver (exhibiting a relatively high content of sn-2 AA), it was hypothesized that iPLA2¥
may playa role in cellular signaling [129].
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Both iPLA2¥ and iPLA2P were demonstrated to participate in hormone-induced
differentiation of preadipocytes using RNA interference and R- and S-BEL [142].
Temporal patterns of iPLA2 expression during differentiation were described and use of
the siRNA and pharmacological inhibitors for both isoforms prevented differentiation
[142].

In addition, increased expression of the 63 kDa isoform of iPLA2¥ was

demonstrated by immunoblot analysis in obese vs. lean rats [142]. These results suggest
that iPLA2 enzymes (including iPLA2¥) may be involved in the progression of obesity.
Most recently, Mancuso et al. showed that mice genetically ablated of iPLA2¥ were
resistant to high fat diet-induced weight gain and insulin resistance[134].

Human platelets possess a cytosolic isoform of iPLA2¥ of approximately 50 kDa [130].
Similar to ventricular myocytes and aortic. endothelial cells, platelet iPLA2y is activated
by thrombin and the activation is completely blocked by BEL [130].

Thrombin

stimulation caused the BEL-sensitive production of AA, lysoPlasC, and thromboxane A2
over the course of several minutes [130].

iPLA2Y mediated platelet activation may

represent another potentially inhibitable function of iPLA2Y in multiple settings where
clotting is unwanted.

Conclusions and Rationale. In conclusion, acute kidney injury (AKI) and chronic
kidney disease (CKD) are becoming more prevalent and have high morbidity and
mortality that have been unchanged for many years.
47

Current therapeutics targeted

towards preventing or treating kidney injury and disease have been unsuccessful.
Calcium-independent phospholipase A2Y (iPLA2y) is one of seven Ca2+-independent
PLA2 enzymes and represents a potential thearapeutic target in kidney disease [81]. Our
studies in renal cells showed that iPLA2Y has a unique subcellular localization in that its
expression and activity were found in both the endoplasmic reticulum (ER) and the
mitochondria, while iPLA2P activity was not present [68, 97-98]. We also determined
that iPLA2Y has divergent roles in cell injury and death, which may be explained by
unique roles and functions within subcellular compartments [81]. Recent studies in our
laboratory using iPLA2y-specific shRNA to decrease iPLA2y activity and expression in
RPTC confirmed its role in preventing lipid peroxidation and preserving mitochondrial
function and viability under basal conditions [116].

While the loss of mitochondrial

iPLA2y was correlated with decreased mitochondrial uncoupled respiration, these studies
pointed to ER- iPLA2y in the lipid peroxidation repair/prevention pathway because
knockdown of ER- iPLA2y was correlated with increased lipid peroxidation. However,
no studies have elucidated the role of iPLA2Y in the ER nor has the mechanism by which
iPLA2¥ preserves phospholipid homeostasis been determined. The goals of these studies
are to elucidate the role of ER- iPLA2¥ in oxidant-induced ER lipid peroxidation, loss of
lipid homeostasis, Ca2+ release and renal cell death.

Recently, Mancuso et al. generated mice null of iPLA2¥ by genetically ablating the
enzyme's active site [136].

These mice were more vulnerable to cardiac stress

(transverse aortic constriction), resistant to high fat diet-induced weight gain, and
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exhibited cognitive dysfunction and multiple bioenergetic dysfunctional phenotypes, such
as cold intolerance and reduced exercise endurance[134-136]. These consequences of
genetic ablation of iPLAl'Y were attributed to loss of cardiolipin (a lipid found primarily
in mitochondria) homeostasis, resulting in mitochondrial dysfunction.

Interestingly,

y oda et al. also generated mice null of iPLA2y and reported in skeletal muscle, increased

lipid peroxidation, the induction of oxidative stress related proteins, and, similarly to the
work of Mancuso et aI., alterations in cardiolipin content and mitochondrial
dysfunction[141].

Additionally, these findings provide evidence that loss of iPLA2y-

induced oxidative stress and mitochondrial dysfunction leads to organ dysfunction in
brain, heart, and skeletal muscle. However, the role of ER- iPLA2y in oxidant- or genetic
ablation- induced lipid peroxidation has not been investigated nor has its role in organ
dysfunction been elucidated.

Based on the current knowledge of the pathophysiology of AKI and CKD and the biology
of PLA2 enzymes, especially iPLA2 in the kidney, the current project was developed.
The specific aims were as follows: 1) to determine the role of ER- iPLA2y in oxidantinduced lipid peroxidation, Ca2+ release, and renal cell death, 2) to elucidate the
mechanism by which ER-iPLA2Y maintains phospholipid homeostasis following oxidant
injury and 3) determine the consequences of iPLA2y ablation in vivo on kidney function
and oxidant injury.
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Chapter 2
Visualization and quantification of endoplasmic reticulum Ca2+ in renal cells using
confocal microscopy and Fluo5F

ABSTRACT

Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular
Ca2+, and its release is an important trigger of physiological and cell death pathways.
Previous work in our laboratory revealed the importance of ER Ca2+ in toxicant-induced
renal proximal tubular cell (RPTC) death. The purpose of this study was to evaluate the
use of confocal microscopy and Flu05F, a low affinity Ca2+ indicator, to directly monitor
changes in RPTC ER Ca2+. Fluo5F staining reflected ER Ca2+, resolved ER structure, and
showed no colocalization with tetramethyl rhodamine methyl ester (TMRM), a marker of
mitochondrial membrane potential. Thapsigargin, an ER Ca2+ pump inhibitor, decreased
ER fluorescence by 30% and 55% at 5 and 15 min, respectively, whereas A23187, a Ca2+
ionophore caused more rapid ER Ca2+ release (55% and 75% decrease in fluorescence at
5 and 15 min).
Carbonylcyanide-p-trifluoromethoxyphenylhydrazone

(FCCP),

a

mitochondrial

uncoupler, added at the end of the experiment, further decreased ER fluorescence after
thapsigargin treatment, revealing that thapsigargin did not release all ER Ca2+. In
contrast, FCCP did not decrease ER fluorescence after A23187 treatment, suggesting
complete ER Ca2+ release. ER Ca2+ release in response to A23187 or thapsigargin
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resulted in a modest but significant decrease in mitochondrial membrane potential. These
data provide evidence that confocal microscopy and Flu05F are useful and effective tools
for directly monitoring ER Ca2+ in intact cells.
Introduction

Ca2+ acts as a universal second messenger and regulates numerous cellular functions
including metabolism, motility, and transport [44]. Loss of Ca2+ homeostasis is critical to
many disease processes and is a major component of cell death pathways including
necrosis, apoptosis, and autophagy [45-51]. Sarcoplasmic/endoplasmic reticulum (ER)
Ca2+ is the most abundant store of intracellular Ca2+and its disruption often initiates the
deleterious cascade of events leading to cell death and dysfunction [48-54].
Traditional methods of measuring of ER Ca2+ are indirect or require difficult probe
loading techniques (i.e. membrane permeabilization, microinjection, or fused cell
hybrids). For example, human embryonic kidney cells require 1 h of dye loading (2 flM
Fluo-3 at room temperature) and extracellular Ca2+ chelation using BAPTA or EGTA,
just to monitor increases in cytosolic Ca2+ as an indirect measure ofER Ca2+ stores [143].
To monitor ER Ca2+ directly, Montero and Robert et al. engineered an ER-targeted
aequorin chimera, a Ca2+-sensitive photoprotein with a lower affinity for Ca2+. However,
in HeLa and skeletal muscle cells, the aequorin chimera was rapidly saturated by the high
Ca2+ concentrations within the ER and required a non-physiological reduction of ER Ca2+
to detect changes in Ca2+ stores [144-145].
Primary cultures of renal proximal tubular cells (RPTC) are highly aerobic,
gluconeogenic, and exhibit robust transport capacity, making them ideal for the study of
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kidney tubular function and injury [146-147]. Previous work in our laboratory revealed
the importance of ER Ca2+ in toxicant-induced kidney injury; although, the mechanism
by which Ca2+ plays such a pivotal role is not completely understood [48, 50, 52-53, 68,
112].
Confocal mIcroscopy is a useful method for the visualization and quantification of
fluorophores at the subcellular level in living cells, and is compatible with most Ca2+
indicators. Chemical fluorescent (UV and visible-wavelength excitation fluorescent
indicators) and bioluminescent calcium indicators (Ca2+ binding photoproteins and GFPbased

Ca2+

indicators)

differ

in

their

characteristics

(loading

requirements,

excitation/emission spectrum, permeability, compartmentalization, relative brightness,
and Ca2+ affinity) and have inherent drawbacks (i.e., dye leakage, cytotoxicity, bleaching,
autofluorescence, intracellular buffering, and lack of ion specificity)[148]. FluoSF is a
chemical fluorescent Ca2+ indicator with a lower affinity for Ca2+ (Kd ---2.3 ~M), limited
cytoxicity and bleaching, and high Ca2+ specificity, making it ideal for studying ER Ca2+.
The purpose of this study was to evaluate the use of confocal microscopy and Fluo5F for
directly monitoring changes in ER Ca2+ in RPTC.

MATERIALS AND METHODS
Materials
Female New Zealand White rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry
(Thompson Station, TN). Tetramethyl rhodamine methyl ester (TMRM) and Fluo-SFAM were purchased from Molecular Probes, Invitrogen (Carlsbad, CA). All other
chemical and materials were obtained from Sigma Chemical (St. Louis, MO).
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Isolation of Rabbit RPTC and Culture Conditions
Rabbit RPTC were isolated using the iron oxide perfusion method and grown to
confluence in 3S-mm tissue culture dishes under improved conditions as previously
described [146-147]. The culture medium was a 1:1 mixture of Dulbecco's modified
Eagle's mediumIHam's F-12 medium (without glucose, phenol red, or sodium pyruvate)
supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 JlM pyridoxine HCI, 15
mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml),
human transferrin (5 Jlg/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (SO
JlM) were added daily to fresh culture medium.

RPTC Loading
RPTC were loaded with 2 JlM Fluo-SF-AM (FluoSF) and 100 nM TMRM for 20 min at
37° C, washed twice with 37° C phosphate buffered saline, and media was replaced.
Then, 1 flM FluoSF and 40 nM TMRM were added to the media to maintain dye
equilibrium and incubated for 30 min at 37° C prior to imaging. The TMRM loading
protocol was modified from Lemasters and Ramshesh [149].

Microscopic Imaging and Analysis
RPTC were imaged on a Leica Microsystems, TCS SP2 AOBS laser scanning confocal
microscope (LSCM) using standardized pinhole, gain, and black level settings. A 63XO.9
NA water-immersion objective was used in an upright microscope configuration. All
images were acquired at 8-bit resolution and at 1024XI024 with a line averaging of two.
RPTC were monitored for 10 min prior to treatment to establish baseline. Then, RPTC
were treated and monitored an additional 15 min prior to Carbonylcyanide-pS3

trifluoromethoxyphenylhydrazone (FCCP, 1 J.!M) addition to depolarize mitochondria.
Images were acquired in I-min intervals during the course of experiments. To quantify
data, images were analyzed using Adobe Photoshop. Mean intensities of images in the
green and red channel after background subtraction were interpreted as a quantitative
measure of ER Ca2+ and mitochondrial membrane potential, respectively. Values are
graphed as the percent mean intensity of each subsequent image vs. mean intensity of the
image taken at time zero. Images comprise of7-10 cells.
Statistical Analysis

RPTC isolated from one animal represents one experiment (N==I). Data are presented as
means ± SE, and multiple means were compared using Student-Newman-Keuls test at
each time point. Means with values p<0.05 were considered statistically significant.

RESULTS AND DISCUSSION

To investigate the use of confocal microscopy to monitor ER Ca2+ dynamics in RPTC,
Flu05F fluorescence was monitored as described above (Fig. 2-1a). Flu05F fluorescence
revealed a reticular pattern around nuclei void of staining. The peripheral granularity of
staining and scarcity of staining at the cell margins provided evidence that the probe is
not fluorescing in the cytosol. To confirm that Flu05F was not in the mitochondria, RPTC
were loaded with tetramethyl rhodamine methyl ester (TMRM) , a marker of polarized
mitochondria. TMRM staining (Fig. 2-1 b) had a punctuate/tubular pattern unlike Flu05F
staining with no co-localization (Fig. 2-1 c), confirming that Flu05F does not reflect
mitochondrial Ca2+, the second most significant storage/buffering compartment for
intracellular Ca2+ [ 47] .
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A

c

B

Figure 2-1. Morphology of Renal Proximal Tubule Cells (RPTC) co-loaded with
Fluo5F and TMRM using confocal microscopy. RPTC were co-loaded with Flu05F (2
JlM) and TMRM (100 nM) as described in the materials and methods. Green
fluorescence of Flu05F and red fluorescence of TMRM were imaged by laser scanning
confocal microscopy. The white bar represents 10 Jlm. Flu05F fluorescence (A)
represents endoplasmic reticulum (ER) Ca2+, TMRM fluorescence (B) represents
polarized mitochondria, and there was no co-localization (C).

We investigated the use of Flu05F to monitor real-time changes in RPTC ER Ca2+.

TMRM was used to measure mitochondrial membrane potential. In control cells, both
Fluo5F and TMRM fluorescence intensity, morphology, and resolution were maintained
over time (Fig. 2-2). Carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a
mitochondrial uncoupler, was added at the end of each experiment to cause mitochondrial
depolarization and indirectly ER Ca2+ release, due to A TP depletion and cessation of
sarcoplasmic/ER Ca2+ ATPase (SERCA) activity.
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Figure 2-2. ER Ca 2+ release RPTC exposed to A23187 and thapsigargin. RPTC were
loaded with Fluo5F and TMRM (see in Fig. 1-1), monitored for 10 min to establish
baseline, exposed to diluent (DMSO, Control), A23187 (10 J..lM), or thapsigargin (10 J..lM)
for 15 min, and then exposed to FCCP (1 J.!M), a mitochondrial uncoupler. Open arrows
represent time of A23187 or thapsigargin treatment and closed arrows represent the
addition of FCCP. Green fluorescence (A) and red fluorescence (B) represents ER Ca 2+
and mitochondrial polarization, respectively. Note the more rapid ER Ca2+ release (A) in
response to A23187 exposure compared to thapsigargin and the rapid loss of
mitochondrial polarization (B) in response to FCCP.

We then explored the effects of two pharmacological agents known to alter ER Ca

2

+.

RPTC were treated with the SERCA inhibitor, thapsigargin, and the Ca2+ ionophore,
A23187. Thapsigargin decreased ER Ca2+ over several min (Fig. 2-2A), which was more
indicative of ER Ca2+ leakage than receptor-dependent ER Ca2+ release that is
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characterized by DAG, ryanodine, and IP 3 receptor sensitive stores [44, 150-151]. In
contrast, A23187 caused a more rapid release of ER Ca2+, an anticipated finding due to
its ionophore activity.
Temporal and incremental changes in ER Ca2+ release and mitochondrial membrane
potential were quantified (Fig. 2-3). A23187 decreased fluorescence by 50% and 70% at
5 and 15 min after treatment, respectively, and FCCP addition did not decrease
fluorescence further. Thapsigargin decreased fluorescence by 25% and 55% at 5 and 15
min after treatment, respectively. In contrast to A23187, FCCP addition further decreased
fluorescence after thapsigargin, providing evidence that thapsigargin did not completely
release all ER Ca2+ stores under these conditions.
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Figure 2-3. Quantification of A23187- and thapsigargin- induced ER Ca2+ release in
RPTC. RPTC were co-loaded with Flu05F and TMRM, treated as described in fig. 2, and
images acquired as described in Materials and Methods. Values are mean intensities of
images in the green channel ± SE and loss of intensity represents ER Ca2+ release. The
open arrow represents exposure to A23187, thapsigargin, or diluent control and the
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closed arrow represents the addition of FCCP. Note the more rapid ER Ca2+ release after
A23187 exposure compared to thapsigargin and an additional loss of fluorescence with
FCCP following thapsigargin exposure.

The advantage of this approach is that ER Ca2+ stores are measured directly, allowing
observation of spatiotemporal differences between A23187- and thapsigargin-induced ER
Ca2+ release that would otherwise be masked by measuring cytosolic free Ca2 +.
Interestingly, Jiang et ale reported a higher rate and magnitude of cytosolic Ca2+ increase
in response to A23187 over thasigargin using Fluo-3, but this approach required chelation
of extracellular Ca2+ prior to treatment [143].
The effect of ER Ca2+ release on mitochondrial polarization was monitored using TMRM
(Fig. 2-4). A23187- and thapsigargin-induced ER Ca2+ release decreased TMRM
fluorescence by approximately 10%. In contrast, FCCP, the mitochondrial uncoupler
added at the end of each experiment, decreased TMRM fluorescence by 60%, reflecting
complete mitochondrial depolarization. Together, these data reveal that ER Ca2+ release
produced by A23187 or thapsigargin partially decreases mitochondrial polarization and is
consistent with previous reports [152].
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Figure 2-4. Quantification of A23187- and thapsigargin-induced mitochondrial
depolarization in RPTC. See above for experimental details. Values are mean
intensities of images in the red channel ± SE and loss of intensity represents
mitochondrial depolarization. The open arrow represents exposure to A23187,
thapsigargin, or diluent control and the closed arrow represents the addition of FCep.
Note the decrease in mitochondrial polarization following A23187 or thapsigargin
exposure compared with control and the rapid loss of mitochondrial polarization
following Feep exposure in all groups.

In conclusion, confocal microscopy and Flu05F are valuable tools for visualization of
spatiotemporal dynamics of ER Ca2+ release in complex cellular systems in real time and
will aid in our understanding of cellular dynamics and death.
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Chapter 3
The Role of Endoplasmic ReticulumCa 2+-Independent Phospholipase A 2y in
Oxidant-induced Lipid Peroxidation, Ca 2+ Release, and Renal Cell Death

Abstract

Oxidant-induced lipid peroxidation and cell death are major components of ischemiareperfusion and toxicant injury. Our previous studies showed that renal proximal tubular
cells (RPTC) express Caz+-independent phospholipase Azy (iPLAzY) in endoplasmic
reticulum (ER) and mitochondria and that iPLA2y is cytoprotective. Our present studies
reveal the role ofER- iPLA2y in oxidant-induced ER lipid peroxidation, Ca2+ release, and
cell death. Oxidant tert-butyl hydroperoxide (TBHP) caused ER lipid peroxidation and
Ca2+ release in isolated rabbit kidney cortex microsomes. ER- iPLA2y inhibition, using
bromoenol lactone (BEL), potentiated both oxidant-induced ER lipid peroxidation and
Ca2+ release. Assessment of fatty acids using electrospray ionization-mass spectrometry
revealed that ER- iPLA2y mediates the TBHP-induced release of arachidonic acid (20:4),
linoleic acid (18:2), and their oxidized forms (18:2-0H, 18:2-00H, 20:4-0H, 20:4-00H,
20:4-(OH)3).

iPLA2Y inhibition also accelerated oxidant-induced ER Ca2+ release in

RPTC. Depletion of RPTC ER Ca2+ stores with thapsigargin, an ER Caz+ pump inhibitor,
prior to TBHP exposure reduced necrotic cell death and blocked the potentiation of
TBHP-induced necrotic cell death by BEL. Together, these data provide strong evidence
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that ER- iPLA2y protects renal cells from oxidant-induced necrotic cell death by releasing
unsaturated and/or oxidized fatty acids from ER membranes, thereby preserving ER
membrane integrity and preventing ER Ca2+ release.

Introduction

Phospholipase A2 (PLA2) enzymes catalyze the hydrolysis of fatty acids at the sn-2
position of glycerophospholipids resulting in the production of a free fatty acid and a
lysophospholipid [86]. Free fatty acids and their metabolites are biologically active in
such processes as inflammation, cell signaling, and cell death. Arachidonic acid, for
example, is metabolized to prostaglandins, prostacyclins, thromboxanes and leukotrienes,
all of which playa role in inflammatory responses and cell signaling [87]. The resulting
lysophospholipids serve as substrates for the re-esterification of free fatty acids by CoAdependent acyltransferases and are also cell signaling molecules [82]. The deacylation
and reacylation of phospholipids is termed "The Lands Cycle" and may be involved in
membrane remodeling

and the

maintenance of membrane homeostasis under

physiological and pathological conditions.

However, there are limited studies

investigating this phenomenon in cellular systems [88].
Calcium-independent phospholipase A2Y (iPLA2Y is one of seven Ca2+-independent PLA2
enzymes [81]. Our studies in renal cells showed that iPLA2y has a unique subcellular
localization in that its expression and activity were found in both the endoplasmic
reticulum (ER) and the mitochondria, while iPLA2Y activity was not present [68, 97-98].
We also determined that iPLA2y has divergent roles in cell injury and death, which may
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be explained by unIque roles and functions within subcellular compartments [81].
Pharmacological inhibition of iPLA2'Y with the selective inhibitor bromoenol lactone
(BEL) reduced cisplatin-induced apoptotic renal proximal tubule cell (RPTC) death and
prevented Ca2+- induced mitochondrial permeability transition by preventing arachidonic
acid release in isolated mitochondria [112-113].

In contrast, iPLA2y inhibition

potentiated oxidant-induced lipid peroxidation and necrotic RPTC death [68, 98]. These
data implicate iPLA2Y as a mediator of apoptotic cell death and as a protectant in oxidantinduced necrotic cell death.
Recent studies in our laboratory using iPLA2y -specific shRNA to decrease iPLA2y
activity and expression in RPTC confirmed its role in preventing lipid peroxidation,
maintaining phospholipid homeostasis, and preserving mitochondrial function and
viability under basal conditions [116].

While the loss of mitochondrial iPLA2y was

correlated with decreased mitochondrial uncoupled respiration, these studies pointed to
ER- iPLA2Y in the lipid peroxidation repair/prevention pathway because knockdown of
ER- iPLA2Y was correlated with increased lipid peroxidation. However, no studies have
elucidated the role of iPLA2Y in the ER nor has the mechanism by which iPLA2y
preserves phospholipid homeostasis been determined. The goals of the present study
were to understand the role of ER-iPLA2Y in oxidant-induced ER lipid peroxidation, fatty
acid release, Ca2+ release and necrotic cell death.
Materials and Methods

Female New Zealand White rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry
(Thompson Station, TN). FIuo-4 pentapotassium salt and FIuo-SF-AM (Fluo5F) were
62

purchased from Molecular Probes Invitrogen (Eugene, OR). All other chemicals and
materials were obtained from Sigma Chemical (St. Louis, MO) or reported previously
[68,97-98,112,116,153].
Isolation of Microsomes. Microsomes were isolated by differential centrifugation from

homogenized rabbit kidney cortex in ice-cold isolation buffer 1 (270 mM sucrose, 5 mM
Tris-HCL, 1 mM EGTA, pH 7.4) for lipid peroxidation studies as described by Kinsey et
al. or isolation buffer 2 (210 mM mannitol, 70 mM sucrose, 2 mM HEPES, pH 7.4) for
Ca2+ uptake studies as described by Schieppati et al. [98, 154]. Microsomes were
resuspended for immediate use in lipid peroxidation buffer (150 mM KCL, 30 mM TrisHCL, pH 7.4) at 2 mg/ml, loaded with cis-parinaric acid (12.8 JlM) on ice for 10 min,
pelleted by centrifugation, washed, and resuspended at 10 mg/ml in lipid peroxidation
buffer. Microsomes were resuspended in isolation buffer 2 at 10 mg/ml for Ca2+ uptake
studies. Aliquots of micro somes were resuspended in 250 mM sucrose, 10 mM KCL, 10
mM imidazole, 5 mM EDTA, 2 mM DTT, 10% glycerol at 10 mg/ml and stored at _80

0

C, under nitrogen, until mass spectrometry analysis.
Measurement of Microsomal Lipid Peroxidation. A fluorescent lipid, cis-parinaric

acid, was used to measure ER lipid peroxidation as described previously [98]. Briefly,
micro somes (400 Jlg) were added to a 96-well plate and incubated with diluent,
inhibitors, or antioxidants at room temperature for 20 min and then treated with 200 JlM
TBHP (final volume 0.2 ml in lipid peroxidation buffer). Membrane peroxidation was
0

measured at 37 C as the loss of cis-parinaric acid fluorescence (excitation 320 nm,
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emission 405 nm) over time using a Fluoroskan Ascent fluorescent plate reader (Thermo
Labsystems, Franklin, MA).
Isolation and Identification of Released Microsomal Fatty Acids.
Thirty minutes following treatment with 200

~M

TBHP or diluent, 5 wells of each group

were pooled and the reaction was stopped by the addition of 50

~M

butylated

hydroxyanisole (BHA) and 0.5 ml methanol. To separate microsomes from released fatty
acids, the reaction mixture was centrifuged at 12,000g for 20 min and supernatant
removed. Lipids were extracted from the supernatant by the Bligh and Dyer method as
modified by Zhang et aI., evaporated under a stream of nitrogen gas to near dryness, resuspended in 100

~L

2: 1 chloroform:methanol, and subjected to electrospray ionization-

mass spectrometry [155-156].
Electrospray Ionization-Mass Spectrometry (ESI-MS).

ESI-MS analysis was

performed as described previously using a Trap XCT ion-trap mass spectrometer (Agilent
Technologies, Santa Clara, CA) with a nitrogen drying gas flow-rate of 30 psi at 350°C
and a nebulizer pressure of 8 L/min [116, 156]. The scanning range was from 100-2200
mlz in the negative ion detection mode on 5

~L

of the sample scanned for 1.4 min with a

mobile phase of acetonitrile:methanol:water (2:3:1) in 0.1% ammonium formate. Fatty
acid species were identified according to their mlz values and confirmed using MSIMS
analysis based on previous studies by Kerwin et aI., and Zhang et aI., [156-158]. The rnlz
values 303, 319, 335, and 351 represent arachidonic acid species 20:4, 20:4-0H, 20:4OOH, and 20:4-(OH)3, respectively. Mlz values 279, 295, and 311 represent linoleic acid
species 18:2, 18:2-0H, and 18:2-00H, respectively. For statistical analysis, rnlz values
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and peak intensities were collected in Microsoft Excel format.

The mlz values were

truncated to the integer and data were aligned using Microsoft Access.

The peak

intensity of each species for each treatment group was compared with that of the control
for that experiment and displayed as % control.

Measurement of Microsomal Ca2+ Uptake and Release. The membrane impermeant
Ca2+ sensitive probe, fluo-4 free acid, was used to measure extramicrosomal Ca2+.
Briefly, micro somes (200 J-lg) were added to a 96 well-plate in Ca2+ uptake buffer (100
mM KCL, 30 mM imidazole-HCI buffer, 5 mM NaN3, 20 mM ammonium oxalate, pH
7.0, ---6 J-lM Ca2+) and incubated with diluent, inhibitors, or antioxidant at room
temperature for 10 min [154]. Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
(SERCA) dependent Ca2+ uptake was initiated by the addition of 2.5 mM MgATP,
micro somes were allowed to load 20-30 min at 37°C, and further loading was inhibited
with thapsigargin (250 nM), a SERCA pump inhibitor. Microsomes were then treated
with 2 mM TBHP and Fluo-4 free acid (200 nM) was added immediately prior to
fluorescence measurements at designated timepoints (excitation 480 nm, emission 520

nm) using a Fluoroskan Ascent fluorescent plate reader (Thermo Labsystems, Franklin,
MA).

Isolation of Rabbit Renal Proximal Tubule Cell (RPTC) and culture conditions.
RPTC were isolated using the iron oxide perfusion method and grown in 35 mm tissue
culture dishes under improved conditions as described previously [146-147]. The culture
medium was a 1: 1 mixture of Dulbecco's modified Eagle's medium/Ham's F -12 medium
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(without glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES
buffer, 2.5 mM L-glutamine, 1 ~M pyridoxine HCI, 15 mM sodium bicarbonate, and 6 mM
lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5
insulin (10 nM), and L-ascorbic acid-2-phosphate (50

~M)

~g/ml),

bovine

were added daily to fresh

culture medium. Confluent monolayers were subjected to treatments as described below.
RPTC Loading and Treatment. RPTC were loaded, as previously described[159]. In

brief, RPTC were co-loaded with 2
incubated with 1

~M

~M

Flu05F and 100 nM TMRM, washed, then

Flu05F and 40 nM TMRM in the extracellular medium. After

loading, RPTC were pretreated with BEL, (S)-BEL, or diluent control (DMSO) and
incubated for 30 minutes.
Microscopic Imaging and Analysis. RPTC were imaged, as previously described, on a

Leica Microsystems,TCS SP2 AOBS laser scanning confocal microscope (LSCM) in an
upright microscope configuration[159]. RPTC were treated with TBHP (500 f.lM) or
diluent control at the start of the experiment and monitored for 1 hour. Images were
acquired in 5-min intervals during the course of experiments. To quantify data, images
were analyzed using Adobe Photoshop. Mean intensities of images in the green and red
channel after background subtraction were interpreted as a quantitative measure ofER
Ca2+ and mitochondrial membrane potential, respectively. Values are graphed as the
percent mean intensity of each subsequent image vs. mean intensity of the image taken at
time zero. Images comprise of 7-10 cells.
Necrotic Cell Death. Necrotic cell death was monitored by measuring propidium iodide

(PI) staining using flow cytometry as previously described [68, 113] . Briefly, RPTC
were exposed to 200 f.lM TBHP or diluent (control) for 4 hrs after pretreatment with BEL
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and/or thapsigargin for 30 min. Media was removed, cells washed, incubated in binding
buffer (10 mM HEPES, 140 mM NaCI, 5 mM KCI, 1 mM MgCI2, 1.8 mM CaCI2, pH
7.4) containing PI (25 Jlg/ml), and washed again in binding buffer without PI. Cells were
then removed from the monolayer using a rubber policeman and subjected to flow
cytometry (Becton Dickinson Facscalibur).
Statistical Analysis.
experiment (n

=

Microsomes/RPTC isolated from one rabbit represents one

1). The appropriate analysis of variance (ANOV A) was performed for

each data set and individual means were compared using Fisher's protected least
significant difference test with P < 0.05 being considered indicative of a statistically
significant difference between mean values.

Results
The fluorescent lipid cis-parinaric acid was used to monitor oxidant-induced lipid
peroxidation in microsomes. cis-Parinaric acid incorporates into the membrane and loses
fluorescence when oxidized [160].

Treatment of microsomes with tert-butyl

hydroperoxide (TBHP) caused an increased rate of lipid peroxidation compared with
controls, and this increased rate was prevented by the addition of an antioxidant,
butylated hydroxyanisole (BHA) (Figure 1). iPLAty is selectively sensitive to
pharmacological inhibition by racemic BEL and enantiomer (R)-BEL but is less sensitive
to enantiomer (S)-BEL [97, 124]. In these studies we used (S)-BEL as a negative control
for iPLA2Y inhibition. Microsomes pretreated with (R)-BEL exhibited a greater rate of
lipid peroxidation than TBHP alone while pretreatment with (S)-BEL (negative control)
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had no effect (Figure 3-1). In summary, iPLAty diminished TBHP-induced ER lipid
peroxidation.
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Figure 3-1 (A) Effect of iPLAiY inhibition on TBHP-induced ER membrane
peroxidation (representative). Freshly isolated rabbit kidney cortex microsomes (ER)
were incubated with the fluorescent lipid cis-parinaric acid, washed, pretreated with
diluent control, 16 f.lM (R)-BEL, 16 f.lM (S)-BEL, or the antioxidant BHA (50 f.lM), and
then treated with 200 f.lM TBHP. The loss of cis-parinaric acid fluorescence (indicative of
lipid peroxidation) was monitored over time (minutes). Results are displayed as percent
initial fluorescence. (B) Effect of iPLAty inhibition on TBHP-induced ER membrane
peroxidation. To determine the rate of lipid peroxidation, data was plotted as percent
initial fluorescence for each treatment group and linear regression analysis was
performed. Oxidation rates are displayed as percent TBHP alone. Means with different
superscripts are significantly different from each other (P < 0.05) n=5. Values are means
± SE.

To determine the lipids released from microsomes during oxidative stress, we employed
electrospray ionization-mass spectrometry (ESI-MS). The resulting ESI-Mass Spectra
revealed that micro somes release several lipid species previously identified in the
literature [156-158] and these species were sufficiently ionized and resolved for further
mass spectrometric analysis (Figure 3-2A).
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Because we were interested in the

mechanism by which iPLA2y prevents lipid peroxidation, we focused on linoleic (18:2)
and arachidonic acid (20:4) species, products of iPLAiy-mediated cleavage of
phospholipids. TBHP caused a 1.7 -fold or greater release of arachidonic acid, linoleic
acid, and their oxidized forms (18:2-0H, 18:2-00H, 20:4-0H, 20:4-00H, 20:4(OH)3)
(Figures 3-2A and 3-2B).

Pretreatment of microsomes with BEL prevented TBHP-

induced release of all linoleic acid species (18:2, 18:2-0H, 18:2-00H), arachidonic acid
species 20:4 and 20:4-00H, and partially prevented the release of 20:4-0H and
20:4(OH)3. These data provide evidence that iPLA2Y mediates oxidant-induced release of
oxidized and unsaturated fatty acids.
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Figure 3-2 (A). Representative Spectrum of Fatty Acids Released from Rabbit
Kidney Cortex Microsomes using Electospray Ionization-Mass Spectrometry.
Released lipids were separated from micro somes using differential centrifugation,
extracted by Bligh Dyer method, injected directly into ESI-Mass Spectrometer, and
analyzed in negative mode.
Peaks of different mlz values represent different lipid
species. Arachidonic Acid (20:4), Linoleic Acid (18:2) and their oxidized forms were
confirmed by MS/MS. (B) Effect of iPLA2Y inhibition on TBHP-induced Linoleic Acid
(18:2) Release. Microsomes were pretreated for 20 min with BEL or diluent, treated for
30 min with 200 f.lM TBHP, and reaction was stopped and analyzed by ESI-MS.
Linoleic Acid (18:2) and its oxidized forms (18:2-0H, 18:2-00H) were identified
according to their mlz values and confirmed by MS/MS analysis. Results are displayed
as peak intensity of treatment group over peak intensity of control X 100 for each lipid
species. Means with different superscripts are significantly different from each other (P <
0.05) n=4-6. Values are means ± SE. (C) Effect of iPLA2y inhibition on TBHP-induced
Arachidonic Acid (20:4) Release. Microsomes were pretreated for 20 min with BEL or
diluent, treated for 30 min with 200 f.lM TBHP, and then reaction was stopped and
analyzed by ESI-MS. Arachidonic Acid (20:4) and its oxidized forms (20:4-0H, 20:4OOH, 20:4-(OH)3) were identified according to their mlz values and confirmed by
MS/MS analysis. Results are displayed as peak intensity of treatment group over peak
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intensity of control X 100 for each lipid species. Means with different superscripts are
significantly different from each other (P < 0.05) n=4-6. Values are means ± SEe

To investigate the role of iPLAiY in oxidant-induced ER Ca2+ release, we developed an
assay to monitor ER Ca2+ uptake and release in microsomes. Fluo-4 fluorescence was
used to monitor extra-microsomal Ca2+. A decrease in fluorescence corresponds to ER
Ca2+ uptake while an increase represents ER Ca2+ release. The addition of A TP caused
rapid Ca2+ uptake (loading) as indicated by a decrease in fluorescence (Figure 3-3).
Pretreatment with thapsigargin, an inhibitor of the Sarcoplasmic/Endoplasmic Reticulum
ATPase (SERCA), prevented the A TP dependent Ca2+ loading.

The addition of

thapsigargin at 30 min prevented further Ca2+ loading but did not cause significant Ca2+
release. A23187, a Ca2+ ionophore, caused rapid release of loaded Ca2+.
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Figure 3-3.
SarcoplasmiclEndoplasmic Reticulum Ca2+ ATPase (SERCA)
de~endent calcium uptake in rabbit kidney cortex microsomes. SERCA dependent
Ca + uptake was initiated by the addition of 2.5 mM ATP and microsomes were loaded
with Ca2+ (ATP). As controls, microsomes were pretreated with thapsigargin (SERCA
inhibitor) prior to ATP addition (ATP+Pre-Tg), thapsigargin was added 30 min after
loading was initiated (ATP+ Tg), or no ATP (diluent) was added (No ATP). 200nM
Fluo-4 salt was added immediately prior to fluorescence readings at the specified time
points. Means with different superscripts are significantly different from each other (P <
0.05) n=3. Values are means ± SE.

To test whether an oxidant causes microsomal Ca2+ release and whether iPLA2Y plays a
role in that release, we loaded microsomes with Ca2+ by adding ATP for 30 min and then
treated with thapsigargin to prevent further loading. Microsomes were then treated with
TBHP or diluent in the presence or absence of iPLA2y inhibition using BEL. Ca2+ release
occurred approximately 50 min after treatment with TBHP and pretreatment with BEL
potentiated the release (Figure 3-4A).

Time is plotted from the addition of TBHP.
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Pretreatment with (S)-BEL was no different than TBHP alone and antioxidant BH.A
prevented oxidant-induced ER Ca2+ release (Figure 3-4B).

In summary, iPLA2y

diminished TBHP-induced Ca2+ release and ER Ca2+ release occurs after the initiation of
lipid peroxidation.
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Figure 3-4 (A) Effect of iPLA2¥ inhibition on TBHP-induced Microsomal Ca 2+
Release. Microsomes were pretreated at room temperature with 10 J.lM BEL or diluent
for 10 min, loading was initiated by the addition of ATP at 37°C, and further loading was
inhibited at 30 min by thapsigargin (Control). Microsomes were then treated with 2 mM
TBHP in the presence (TBHP + BEL) or absence (TBHP) of BEL. Fluo-4 acid was added
immediately prior to fluorescence readings at specified time points and results displayed
as percent control fluorescence (microsomes loaded and treated with thapsigargin alone).
Means with different superscripts are significantly different from each other (P < 0.05)
n=4. Values are means ± SE. (B) The role of iPLA2y in TBHP-induced ER Ca2+ Release
at 80 minutes (50 minutes after treatment with TBHP). Microsomes were pretreated with
diluent, BEL, (S)-BEL (negative control), or BHA (antioxidant control) for 10 min at
room temperature. Loading was initiated by the addition of 2.5 mM ATP at 37°C,
micro somes were loaded for 30 min and then treated with diluent (ATP only group), 250
nM thapsigargin (Control), thapsigargin and 2 mM TBHP (TBHP), or thapsigargin and
TBHP after pretreatment with 16 J.lM BEL (TBHP+BEL), 16 J.lM (S)-BEL
(TBHP+SBEL), or 50 J.lM BHA (TBHP+BHA). 200 nM Fluo-4 acid was added
immediately prior to fluorescence measurements 80 minutes after the initiation of
loading. Results were displayed as (treatment group fluorescence-ATP only group
fluorescence)/(TBHP group fluorescence-ATP only group fluorescence) X 100). Means
with different superscripts are significantly different from each other (P < 0.05) n=5 .
Values are means ± SE.
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To investigate the role of iPLA2y in oxidant-induced ER Ca2+ release in RPTC, cells were
co-loaded with Flu05F, a marker of ER Ca2+, and tetramethyl rhodamine methyl ester
(TMRM) , a marker of polarized mitochondria. Fluorescence was monitored using laser
scanning confocal microscopy (LSCM) as previously described[159].

RPTC were

treated with TBHP in the presence and absence of iPLA 2y inhibition by BEL. Inhibition
of iPLA2'Y prior to TBHP treatment potentiated TBHP-induced ER Ca2+ release (Fig. 5A).
There was no significant loss of mitochondrial polarization in any group during this time
frame (Fig. 3-5B).
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Figure 3-5.
The role of iPLAty in TBHP-induced ER Ca 2+ release and
Mitochondrial Depolarization in RPTC. RPTC were loaded, as described in materials
and methods, pretreated with BEL (5 J.!M) or diluent control for 30 min, exposed to
TBHP (500 J.!M) or diluent control, and then monitored for 1 hr using laser scanning
confocal microscopy. Flu05F fluorescence (green, A) and TMRM fluorescence (red, B)
represents ER Ca2+ and mitochondrial polarization, respectively. Note, TBHP alone did
not induce ER Ca2+ release at 30 minutes. In contrast, TBHP induced ER Ca2+ release in
There were no significant changes in
RPTC pretreated with BEL at 30 min.
mitochondrial polarization.

Quantification of TBHP-induced ER Ca2+ release revealed 15% and 40% ER Ca2+ release
at 30 and 45 min, respectively, in RPTC pretreated with BEL and then exposed to TBHP.
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In contrast, TBHP exposure alone caused no ER Ca2+ release at 30 minutes and only 20%
release at 45 min (Fig. 3-6). Pretreatment with (S)-BEL (negative control) prior to TBHP
exposure was no different than TBHP alone and BEL alone nor SBEL alone caused ER
Ca2+ release. In summary, iPLAty delayed TBHP-induced ER Ca2+ release in RPTC.
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Figure 3-6. Quantification of TBHP- induced ER Ca2+ Release in RPTC. RPTC
were co-loaded, pretreated, exposed to TBHP, and imaged, as described in materials and
methods. Values are mean intensities of images in the green channel ± SE and loss of
intensity represents ER Ca2+ release. Note earlier TBHP-induced ER Ca2+ release under
iPLAty inhibition (TBHP+BEL) compared to TBHP alone(TBHP) and negative control
(TBHP+SBEL). BEL alone nor (S)-BEL alone caused ER Ca2+ release.

The next experiment was designed to investigate the role of ER Ca2+ release in oxidantinduced cell death in RPTC in the presence and absence of iPLAty inhibition. TBHP
caused 30% necrotic cell death (propidium iodide (PI) staining) as compared to 2-3% in
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control cells. iPLA2y inhibition with BEL prior to TBHP treatment potentiated TBHPinduced necrotic cell death to 40% as previously reported [68, 98] (Figure 3-7). When ER
Ca2+ was depleted with thapsigargin prior to TBHP exposure, necrotic cell death was
reduced to 17%. Equally important, the potentiation of cell death observed when iPLA2y
was inhibited was blocked by ER Ca2+ depletion (Figure 3-7).

BEL alone and

thapsigargin alone had no effect on cell viability. In summary, ER Ca2+ release is a major
attributor to oxidant-induced necrotic cell death and the potentiation of cell death seen
under iPLA2y inhibition.
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Figure 3-7. Effect of ER Ca2+ depletion and iPLA2y inhibition on oxidant-induced
RPTC necrosis. RPTC were treated with either diluent (DMSO), BEL, and/or
thapsigargin for 30 min before the addition of TBHP (200 J.lM). After treatment, the
percent PI staining was determined by flow cytometry. Means with different superscripts
are significantly different from each other (P < 0.05) n=5. Values are means ± SE.
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Note, the potentiation of TBHP-induced necrotic cell death by BEL, but the absence of
potentation by BEL when ER Ca2+ stores are depleted with thapsigargin.

Discussion
We previously demonstrated that Ca2+ plays an important role in necrotic renal cell death
[50, 52-53]. In 1997, we demonstrated ER Ca2+ release was a key step in necrotic cell
death and that depletion of ER Ca2+ stores blocked death in RPTC [50]. Other studies in
RPTC revealed that iPLAty inhibition potentiates oxidant induced lipid peroxidation and
cell death, and knockdown of ER- iPLA2'Y correlated with increased lipid peroxidation
and loss of cell viability [68, 98]

These studies demonstrated the cytoprotective role of

iPLA2'Y revealed the significance of ER Ca2+ release during necrotic cell death, and
pointed to ER- iPLA2'Y in the putative lipid peroxidation repair/prevention pathway.
However, a direct link between ER- iPLA2Y and oxidant-induced ER Ca2+ release had not
been established, nor had the mechanism by which ER- iPLA2y is protective or is
involved in the lipid peroxidation repair/prevention pathway been revealed. Thus, the
goals of the present study were to understand the role of ER- iPLA2y in oxidant-induced
ER lipid peroxidation, fatty acid release, Ca2+ release and necrotic cell death.

We used freshly isolated rabbit kidney cortex micro somes to further investigate the role
of ER- iPLA2Y in oxidant stress.

ER- iPLA2y decreased oxidant-induced lipid

peroxidation and Ca2+ release, and mediated oxidant-induced release of oxidized and
unsaturated fatty acids. These results support our hypothesis that ER- iPLA2y protects
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renal cells from oxidant injury by decreasing lipid peroxidation, ER Ca2+ release and
subsequent necrotic cell death. These findings are consistent with our previous work in
isolated mitochondria showing that iPLAiY protects mitochondria from oxidant-induced
lipid peroxidation and mitochondrial swelling [98]. Also, shRNA knockdown of iPLA2y
in RPTC increased lipid peroxidation and sensitized RPTC to nonlethal oxidant treatment
[116].

It has been proposed that phospholipases playa role in membrane remodeling and repair
during oxidant stress by cleaving oxidized and/or unsaturated fatty acids from the
membrane, preventing the initiation and propagation of lipid peroxidation, and allowing
for the incorporation of unoxidized fatty acids [74]. ER and mitochondria are the major
sites of reactive oxygen species (ROS) production and the presence of iPLA2Y in
mitochondria and ER of rabbit RPTC makes it a likely candidate for a role in membrane
repair and remodeling. The most probable mechanism by which these enzymes prevent
or repair lipid peroxidation is through the cleavage and removal of oxidized fatty acids
from the membrane [81].

The initiation step of lipid peroxidation involves the

abstraction of a hydrogen atom from the methylene carbon of a fatty acid and therefore
fatty acids with more double bonds are more vulnerable to the initiation of lipid
peroxidation [75]. The resulting peroxyl radical is capable of abstracting a hydrogen
atom from adjacent fatty acids, thus propagating the lipid peroxidation and potentially
producing several lipid hydroperoxides [76]. This chain of events can be terminated by
the removal of the reactive lipid from the site of reaction or a chain-breaking
antioxidant[75-77].

In our case, the inhibition of iPLA2y would result in the
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accumulation of oxidized fatty acids in the membrane and contribute to the propagation
of the lipid peroxidation.

Van Kujick proposed that hydroxyl or hydroperoxyl groups introduced into fatty acyl
chains via lipid peroxidation creates a more hydrophilic acyl chain that would move
towards the head group of a phospholipid to become more thermodynamically stable
[88]. This molecular rearrangement could make the ester linkage at the sn-2 position
more accessible to PLA2 cleavage.

Interestingly, both oxidized arachidonic acid and

linoleic acid were released following exposure of ER to TBHP. While it may be true that
oxidized fatty acids become more accessible to phospholipase cleavage, it is clear that
iPLAl'Y is readily capable of removing non-oxidized fatty acids under oxidative
conditions. The release of non-oxidized fatty acids, such as arachidonic acid, during
oxidant stress raises the possibility that the non-oxidized arachidonic acid may initiate an
inflammatory signal through one of its metabolites.

This possibility requires further

exploration.

We developed an assay of microsomal Ca2+ release using Fluo-4, a fluorescent dye with a
high affinity for Ca2+ (Km--- 300 nM).

ATP dependent loading was consistent with

Sheippatti et ai., in that it took approximately 20 min to reach maximal Ca2+ uptake [77,
154].

There was little passive Ca2+ loading, as depicted in microsomes incubated

without A TP or pretreated with thapsigargin prior to the addition of A TP. Treatment
with thapsigargin after loading did not cause release of Ca2+ as observed in intact cells
[50]. We used this to our advantage because we were interested in ER Ca2+ release and
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treated microsomes with thapsigargin after loading to ensure that any Ca2+ released may
not be re-sequestered by SERCA activity. There was not a gradual release of ER Ca2+
but a critical point reached approximately 50 min after treatment with TBHP. We did not
observe ER Ca2+ release earlier under conditions of iPLA2Y inhibition, but instead we
observed the potentiation of ER Ca2+ release 50 min after TBHP treatment. These data
provide evidence that iPLA2Y is protective by preventing the propagation of lipid
peroxidation.

To investigate the role of iPLA2y in oxidant-induced RPTC ER Ca2+ release, we utilized
a method developed in our laboratory of monitoring ER Ca2+ directly using low affinity
Ca2+ indicator, Fluo5F, and laser scanning confocal microscopy. These data revealed that
iPLA2Y inhibition resulted in oxidant-induced ER Ca2+ release at an earlier time point
than TBHP alone. Collectively, these data support our hypothesis that ER- iPLA2y
protects renal cells from oxidant-induced necrotic cell death by preventing ER lipid
peroxidation, preserving ER membrane integrity, and blocking ER Ca2+ release and loss
of Ca2+ homeostasis.

Interestingly, iPLAiY inhibition alone was not sufficient to cause ER Ca2+ release within
the course of the experiment. These data suggest that iPLA2y is most important under
conditions of elevated oxidant stress such as would be experienced during
ischemiaireperfusion or toxicant injury. Additionally, our studies in RPTC reveal that
oxidant-induced ER Ca2+ release occurs prior to loss of mitochondrial membrane
potential and cell death.
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2
To confirm ER Ca + release is a mediator of oxidant-induced cell death and that iPLA2y
plays a pivotal role in this process, we depleted the ER of Ca2+ prior to oxidant injury and
monitored necrotic cell death in the presence and absence of iPLA2y inhibition.
2
Depletion of ER Ca + prior to oxidant injury greatly reduced necrotic cell death and
blocked the potentiation of cell death seen under iPLA2Y inhibition. These data reveal
that the protection from necrotic cell death by iPLAty during oxidant injury is closely tied
with ER Ca2+ release. This compilation of evidence supports our hypothesis that ERiPLA2Y is protective during oxidant injury and reveals the mechanisms by which ER
iPLA2Y protects the ER from oxidant-induced lipid peroxidation and Ca2+ release.
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Chapter 4

Genetic Ablation of Ca2+-Independent Phospholipase A2Y Induces Lipid
Peroxidation, Oxidative DNA Damage and Loss of Phospholipid Homeostasis in
Mouse Kidney

Abstract

Calcium-independent phospholipase A 2y (iPLA2y) protects primary renal cells from
oxidant injury by preventing or repairing oxidant-induced lipid peroxidation. We tested
this hypothesis in vivo using mice genetically ablated of iPLA2Y (KO mice) and
investigated its role in age-related renal oxidant injury. Urinary 8-isoprostanes and 8hydroxy-2'-deoxyguanosine (8-0HdG), biomarkers of lipid peroxidation and oxidative
DNA damage, respectively, increased in 13 month KO mice compared to WT mice.
Urinary lipidomic analysis demonstrated decreases in phospholipid species 38:6, 38:5
and 37:5 phosphatidylcholine and increases in 6-10 carbon fatty acids, with methyl or
keto additions. Thirteen month KO mouse kidney cortex exhibited higher lipid
peroxidation and 8-0HdG staining compared to WT mice. No differences in kidney
function were detected between KO and WT mice at 2 or 13 months of age. Renal
mitochondrial respiratory proteins NDUFB8 and COX-I, and mitochondrial DNA copy
number increased in KO mice. KO mice exhibited increased mRNA levels of GPx4, an
antioxidant enzyme that contains lipid hydroperoxidase activity. Collectively, these
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studies reveal that genetic ablation of iPLA2y results in 1) increased renal oxidative lipid
and DNA damage, 2) disruption of mitochondrial homeostasis with increased respiratory
proteins and mtDNA, and 3) a compensatory increase in GPx4.

These data provide

evidence that iPLA2y is critical for the prevention or repair of lipid peroxidation in
oxidative kidney injury.

Introduction
Phospholipase

A2

(PLA2)

enzymes

hydrolyze

the

sn-2

ester

bond

of

glycerophospholipids, producing a free fatty acid and a lysophospholipid [86]. Free fatty
acids serve as signaling molecules and/or can be further metabolized to produce
mediators of inflammation, cell signaling and death. For example, arachidonic acid is
metabolized to prostaglandins, prostacyclins, thromboxanes and leukotrienes; all of
which are major components of inflammatory and signaling pathways

[87].

Lysophospholipids can serve as substrates for the re-esterification of free fatty acids by
CoA-dependent acyltransferases [82]. The ability of PLA2 to release fatty acids from
phospholipid membranes and, in tum, allow for the re-esterification of free fatty acids
from

cellular pools is the basis for its putative involvement in membrane

remodeling/repair pathways; however, their role in these pathways have not been fully
elucidated [88].
iPLA2y is one of seven Ca2+-independent PLA2 and belongs to the Group VIB family.
Our previous studies detected high levels of iPLA2y expression and activity in rabbit
renal cells that were localized to the endoplasmic reticulum (ER) and mitochondria, the
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major sites of reactive oxygen species (ROS) production and targets of oxidant injury
[68, 97-98, 112]. Pharmacological inhibition of iPLA2y potentiated oxidant-induced lipid
peroxidation in isolated mitochondria and ER, and potentiated oxidant-induced
mitochondrial permeability transition (MPT) and ER Ca2+ release, respectively [98, 161].
Pharmacological inhibition of iPLA2y also potentiated lipid peroxidation and necrotic cell
death in renal proximal tubule cells (RPTC) [68]. Recently, we showed that knockdown
of iPLA2Y

using

shRNA

phosphatidylethanolamine,

increased

and

several

speCIes

phosphatidylglycerol

of phosphatidylcholine,

phospholipid

classes

[116].

Additionally, we demonstrated iPLA2y mediated release of oxidized and non-oxidized
fatty acids from the ER during oxidative stress [161]. These data provide strong evidence
that iPLA2Y is a major component of the membrane remodeling/repair pathway and is
thereby protective during oxidant stress in renal cells.
Mancuso et al. generated mice null for iPLA2y by genetically ablating the enzyme's
active site [136]. These mice were more vulnerable to cardiac stress (transverse aortic
constriction), were resistant to high fat diet-induced weight gain, exhibited cognitive
dysfunction and exhibited multiple dysfunctional bio-energetic phenotypes, such as cold
intolerance and reduced exercise endurance, compared to their wild type liter mates [134136].

Interestingly, Yoda et ai. also generated mice null of iPLA2Y

and reported

increased lipid peroxidation in skeletal muscle, and, similarly to the work of Mancuso et
aI., alterations in cardiolipin content and mitochondrial dysfunction [141].

Together,

these data support our previous findings that impairment of iPLA2Y increases oxidative
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stress, alters lipid homeostasis, and increases mitochondrial dysfunction in vitro. The
effects of knocking out iPLAty in the kidney have not been studied.
The goal of these studies was to examine the consequences of iPLA2y loss in the kidney,
particularly with respect to age. Because oxidant stress is a major component of agerelated deterioration of kidney function and iPLA2y protects RPTC from oxidative stress,
we hypothesized that mice genetically ablated of iPLA2Y will have increased levels of
oxidative stress and display altered lipid homeostasis, and that these changes will be more
apparent as mice age.

Experimental Procedures
Mouse Husbandry
Mice of a mixed genetic background of C57BL/6 x 129/Sv with the region encoding the
active site of the iPLA2y removed [136] were a gift from Dr. Richard Gross at
Washington University School of Medicine, St. Louis, MO. Mice were housed In
standard animal rooms under normal conditions: 12 hr dark (18.00-06.00 hr)-12 hr
artificial light (06.00-18.00 hr) cycle; temperature maintained at 21 ± 1°C; and relative
humidity varied between 30 and 60% and received food and water ad libitum.
Heterozygous mice were bred under pathogen-free conditions and the resulting WT and
KO male mice were used for these studies. PCR analysis was performed for genotyping,
as previously described [136].

All studies were reviewed and approved by the

institutional animal care and use committee of the Medical University of South Carolina
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and were in accordance with the National Institutes of Health guidelines for humane
treatment of animals.

Urine and Tissue Collection

For 24 hr urine collection, mice were weighed, and then housed individually in metabolic
cages. Urine samples were centrifuged at 800 g for 5 min, supernatant volume measured
and antioxidant (BHT, 0.05%) added. Samples were either analyzed immediately or
aliquoted and frozen at -80°C for further analysis.

Mice were then euthanized by

intraperitoneal injection of pentobarbital, blood taken via cardiac puncture, and kidneys
collected for tissue analysis. A portion of the kidney was fixed in 10% buffered formalin
for

greater

than

24

hr

and

subsequently

processed

for

histology

or

immunohistochemistry. The remaining kidney tissue was stored at -80°C. Serum was
separated from whole blood by standard methods, BHT added, and was either used
immediately or stored at -80°C.

Urine and Serum Assays

Urine and serum creatinine were measured using a QuantiChrom Creatinine Assay Kit
according to the manufacturer's protocol (Hayward, CA). Each sample was tested in
duplicate and values expressed in mg/dl. 8-isoprostane and 8-0HdG were measured in
urine using ELISA assay kits as markers of lipid peroxidation and oxidative DNA
damage, respectively (Cayman Chemicals, Ann Arbor, MI).

Generally, samples were

diluted 1:20 and 1: 1000 for 8-isoprostane and 8-0HdG, respectively.
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Histology

Renal tissues were fixed in 10% buffered formalin, dehydrated, and embedded in
paraffin. For general histology, sections were stained with hematoxylin/eosin or PAS and
were scored in a blinded fashion by a renal pathologist, Dr. Judit Megyesi, University of
Arkansas for Medical Sciences. Briefly, morphologic damage (tubular necrosis, loss of
brush border, casts, inflammatory cells, tubular dilatation, distal damage, degeneration,
red blood cell extravazation, interstitial edema, glomerular changes, and interstitial
fibrotic foci) of the entire kidney section was scored semi quantitatively using the
following scale: none= 0; <10%= 1; 11-250/0= 2; 26-75%== 3; and 75%== 4.

Immunohistochemistry

Slides were emersed twice in xylene for 5 min and were dehydrated by emersion in
100%, 95% and 70% histological grade ethanol, consecutively, for 6 min each. Slides
were rinsed in PBS, incubated in 30% H2 02 for 30 min, and then incubated in 2% normal
horse serum for 20 min to block non-specific binding. Slides were washed twice with
PBS and incubated with primary antibodies against 8-0HdG (9.75

~g/ml)

for 18 hours.

Slides were washed three times in PBS for 5 min, incubated for 30 min in PBS containing
a universal secondary antibody and Elite Reagent (Vector labs; Burlingame, CA, USA),
and then incubated for 30 min with DAB reagent and Gills Hematoxylin, as a counter
stain. Slides were bathed in ammonium hydroxide (10% V/v) , dehydrated, and
fluoromount and cover slips were applied. Images were taken using a Nikon AZI00
fluorescence microscope and positively stained nuclei per field were counted from three
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random images (25X) in a double blinded fashion.

8-0HdG antibody was purchased

from Rockland Immunochemicals (Gilbertsville, PA, USA).

Tissue Lipid Peroxidation Assay
To measure thiobarbituric acid reacting substances (TBARS), mouse kidney cortex (-----25
mg) was placed in 500 f.ll RIPA Buffer (50 mM Tris-HCL, 150 mM NaCI, 1 % Triton X100, 1% Sodium Deoxycholate, 0.1 % SDS, 1 mM EDTA) containing protease inhibitors
and BHT (0.05%) and sonicated on ice for 15 sec at 1400 V. An aliquot (50 J-lI) was
taken for protein quantification. Samples were centrifuged at 1600 g for 10 min at 4°C
and supernatant used for the assay. Color reagent containing 200 f.ll 8.1 % SDS, 1.5 ml
20% acetic acid (pH=3.5), 1.5 ml 0.8% thiobarbituric acid, and 700 f.ll water was added
vigorously to 100 f.ll sample (supernatant) in a glass vial and boiled for 1 hr at 95°C. To
stop the reaction, the mixture was placed on ice for 10 min, then centrifuged at 3000 g for
10 min. A 200 ul aliquot of supernatant was taken and absorbance measured at 650 nm.
1, 1, 3, 3-Tetraethoxy-propane was used as a standard. Methods were modified from
Ohkawa et al. [162].

Bligh-Dyer lipid extraction
Urine lipids were extracted using chloroform and methanol according to the method of
Bligh and Dyer [155]. Urine (1 mL) was mixed with 2 mL methanol: water (2.0:0.8 v/v),
transferred to a glass test tube, 1.25 ml chloroform was added, and tubes were vortexed
for 30 sec and allowed to sit for 10 min on ice. Tubes were centrifuged at 213 g for 1
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min and the bottom chloroform layer was transferred to a new test tube. The extraction
steps were repeated and the chloroform layers combined.

The collected chloroform

layers were dried under argon, reconstituted with 50 JlL of methanol:chloroform (2:1
v/v), and stored at -20°C.

Lipid phosphorus assay
Lipid phosphorus was quantified using a modified Bartlett inorganic phosphorous assay
[163]. Lipid extract (10 JlL) was mixed with 400 JlL of ION sulfuric acid and heated at
180-200°C for 1 hr in a glass test tube.

After this time, 100 JlL of 30% hydrogen

peroxide was added while vortexing and the tube was heated for an additional 1.5 hr.
The tube was removed from heat and 4.6 mL of molybdate reagent and 100 JlL of 15%
ascorbic acid were added consecutively while vortexing. Samples were then placed in a
boiling water bath for 10 min before absorbance was read at 825 nm.

Characterization and quantitation of urinary lipids using electrospray ionizationmass spectrometry (ESIIMS).
Lipid extract samples (20 pmol/JlI) were prepared by reconstituting in chloroform:
methanol (2: 1, v/v). Samples were analyzed using an Agilent Trap XCT ion-trap mass
spectrometer equipped with an electrospray ion source (Agilent, Santa Clara, CA).
Samples (5 ilL) were introduced by means of a flow injector into the ESI chamber at a
rate of 0.2 mL/min. The elution solvent was acetonitrile:methanol:water (2:3: 1, v/v/v)
containing 0.1 % (w/v) ammonium formate (pH 6.4).
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The mass spectrometer was

operated in both positive and negative scanning mode. The flow rate of nitrogen drying
gas was 8 Llmin at 350°C. The capillary and cone voltages were set at 2.5 kV and 30 V
respectively. Qualitative identification of individual phospholipid and fatty acid species
was based on their calculated theoretical monoisotopic mass values, followed by a
subsequent round of MS to identify fragmentation products (MS/MS).

Relative

abundance was determined by comparison to the total ion count in each sample.

Immunoblot Analysis
Approximately 25 mg of frozen kidney tissues were homogenized and disrupted by
sonication for 30 sec using homogenization buffer supplemented with protease inhibitors.
Equal

amounts

of tissue

homogenates

were

separated

by

SDS-PAGE

and

electrophoretically transferred to nitrocellulose membranes. After treatment with 5%
skim milk for 1 hr at room temperature, membranes were incubated with various
antibodies NDUFB8 & COX I (Invitrogen, Carlsbad, CA ), A TP Synthase

~

(Abeam,

Cambridge, MA) and GAPDH (Fitzgerald, Concord, MA) overnight at 4°C and then
incubated with an appropriate horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at room temperature. Bound
antibodies were visualized after chemiluminescence detection on an AlphaEase FC standalone imaging system (San Leandro, CA).

Mitochondrial DNA Copy Number
Real-time PCR was used to determine relative quantities of mitochondrial DNA content
in WT and KO animal kidney tissues. Total genomic DNA was extracted using a DNeasy
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Blood and Tissue kit (QIAGEN, Valencia, CA). DNA was quantified by measuring A260
values and 50 ng of total DNA was used for PCR, as previously described [164]. Primers
specific to the mitochondrial-encoded ND6 gene were used to assess mitochondrial DNA
copy numbers. Primers designed against the nuclear-encoded tubulin gene were used for
normalization and are listed in Table 4-1.

Gene

Sequence

GPx4

FW: TGT GCA TCCC GCG ATG ATT
REV: CCC TGTACT TAT CCA GGC AGA
FW: GAC ACC TCT TCC TTC GAC TAC C

GR· 1

REV: CCC AGC TTG TGA eTC TCC AC
ND6
Prdx6
Tubu/in

FW: AGG GCTTGG GTTGATTGTTAG
REV: TGC CAT CGC AGTAGT ATA CCC
FW: CAT CCG CTTCCA eGA TTTCCT
REV: eTC TGC CAA GTT CTG TGG TG
FW: CTC TCT GTC GAT TAC GGC AAG
REV: TGG TGA GGA TGG AGT TGT AGG

Table 4-1. Primers used for qRT-PCR experiments

Quantitative Real-Time PCR

Total RNA was isolated from kidney tissues with TRIzol reagent (Invitrogen). cDNA
was synthesized from 1 l-lg of RNA template using a RevertAid™ First Strand cDNA
Synthesis Kit (Fermentas Inc., Glen Bernie, MD). PCR was carried out, as previously
described [19], using 3 f.ll of 1:3 diluted cDNA template combined with Maxima® SYBR
Green qPCR Master Mix (2X) at a final concentration of IX (Fermentas Inc.), ROX
(Fermentas Inc.) and primers (Invitrogen, Carlsbad, CA) at a concentration of 10 nM and
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400 nM respectively. Sequences of primers used for real-time PCRs are listed in Table 41.

Statistical Analysis
Tissues isolated from one mouse represents N = 1. The appropriate analysis of variance
(ANOVA) was performed for each data set and individual means were compared using
Fisher's protected least significant difference test with P < 0.05 being considered
indicative of a statistically significant difference between mean values.

Results

Male KO mice appeared normal at birth and exhibited normal ambulatory activity as
previously described [136]. To assess general phenotypic features of KO mice, we
measured age-related differences in weight (Table 4-2).

There were no significant

differences in weight between male KO and WT mice at 2 months; however, KO mice
did not gain weight after 2 months of age. KO mice were --55% the weight of WT mice
at 13 months.

KO mice at 13 months of age began to show kyphosis and reduced

ambulatory activity. These findings are consistent with previous reports [136, 141].
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2 months

WT

KO

Weight (g)

21 i 1

20

Serum Creatinine (mg/dl)

0.32:!: 0.1

0.36

Urine Volume
(m1/24 hr)/kg

90 :!: 25

Urine Creatinine
(mg/ml)/kg
Creatinine Clearance
(ml/min)/kg

13 months

WT

KO

47:1:1

23 t 1*

0.33 :I: 0.1

0.37 ± 0.1

78 :t 11

20:1: 1

21

675 ±112

595 :1:85

815 t 145

940 t 151

2.8 :to.8

2.0:1:0.6

2.0 ± 0.6

1.7 ±0.5

±1

±0.1

±1

Table 4-2. General age-related phenotypic features and kidney function of iPLA2y /- mice Weight and serum creatinine were measured. Mice were placed in metabolic
cages for 24 hrs and urine volume and urinary creatinine were measured and corrected for
weight.
Creatinine clearance was calculated. Values are means ± SE in the units
designated. Means highlighted with an asterisk denotes mean of KO animals is
significantly different from mean ofWT animals within the age group (N=4-8) p<O.05.

To assess the effects of genetic ablation of iPLA2y on kidney function, we measured
serum and urine creatinine, urine volume and calculated creatinine clearance. There were
no significant differences in these parameters between WT and KO animals at 2 or 13
months when standardized to body weight (Table 4-2). In summary, KO mice did not
display overt changes in renal function.

Kidney histology was evaluated for tubular necrOSIS, loss of brush border, casts,
inflammatory cells, tubular dilatation, distal tubule damage, degeneration, red blood cell
extravasation, interstitial edema, glomerular changes, and interstitial fibrotic foci.
Kidney cortex from 2 month old KO mice exhibited tubular degeneration and loss of
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brush border compared to 2 month WT controls (Fig. 4-1, Table 4-3). Kidney tissues
from 13 month WT controls exhibited increased markers of the aging kidney (i.e. loss of
brush border, tubular dilatation and degeneration, glomerular changes, and interstitial
fibrotic foci). KO mice exhibited similar age-related histological changes except tubular
dilatation was decreased in 13 month iPLA2y KO animals compared to 13 month WT
controls. In summary, while genetic ablation of iPLA2y resulted in some changes of
kidney morphology at 2 months of age compared to WT mice, kidney morphology at 13
months of age was not markedly different between KO and WT mice.
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Figure 4-1. Effects of iPLA2'Y -/- ablation and aging on mice kidney histology.
Periodic Acid/Schiff reagent (PAS) stained sections of 2 and 13 month old iPLAiY KO
and WT mouse kidney at 40X magnification. Tubules highlighted with an asterisk exhibit
loss of brush border and tubular degeneration. Regions outlined in blue exhibit
interstitial fibrotic foci.
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2 months

13 months

WT

KO

WT

KO

Tubular Necrosis

0:1:0

1.3 ±0.8

O±O

0:1:0

Loss of Brush Border

0.2 ± 0.2

2.5 :I: 0.5·

3.3f 0.2

3.0 :1:0.4

Casts

0:1:0

1.3 :I: 0.8

1.5:!: 0.2

0.8:1:0.2

Inflammatory Cells

1.0 :I: 0.5

2.2 :1:0.5

2.5:1:0.2

2.5:1:0.3

Tubular Dilatation

0:1:0

0.7 :1:0.5

2.0 :1:0.3

0.6 ± 0.4*

Distal Damage

O:tO

1.1

0.2fO.2

0.4:1:0.2

Degeneration

0.5:1:0.5

2.3 :to.6*

3.5:1:0.2

3.0±0.2

Red Blood Cell Extravazation

1.0 f 0.4 2.5 :1:0.4

1.5:1: 0.2

1.8 :I: 0.5

Interstitial Edema

0:1:0

0.2:1:0.2

Of 0

0:1:0

Glomerular Changes

0:1:0

Of 0

2.3:tO.2

2.4:1: 0.2

Interstitial Fibrotic Foci

0:1:0

0:1:0

1.9:1:0.2

1.6 :I: 0.2

:I:

0.7

Table 4-3. iPLA2y -/- mice kidney histology and aging. Histological sections of 2 and
13 month iPLA 2y KO and WT mouse kidney sections were stained with
hematoxylin/eosin or PAS and scored in a blinded fashion by a renal pathologist.
Morphological damage in 10-12 fields per section were quantified using the following
scale: none= 0; <10%= 1; 11-25%= 2; 26-75%= 3; and 75%= 4. Values are mean scores
± SE. Means highlighted with an asterisk denotes mean of KO animals is significantly
different from mean of WT animals within the age group.

To investigate the effects of genetic ablation of iPLA2y on oxidant injury in vivo, we
measured

urinary

8-isoprostanes

and

8-hydroxy-2' -deoxyguanosine

(8-0HdG),

biomarkers of lipid. peroxidation and oxidative DNA damage, respectively.

Because

there was no change in serum creatinine, and as creatinine excretion correlated with
weight, we normalized the data to urinary creatinine concentration within each sample.
There were no differences in urinary 8-isoprostanes or 8-0HdG concentrations in KO and
WT mice at 2 months of age (Fig. 4-2). However, 13 month KO mice excreted 9-fold
higher 8-isoprostane and 2-fold higher 8-0HdG compared to 13 month WT mice. In
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summary, genetic ablation of iPLA2y increased markers of lipid peroxidation and
oxidative DNA damage in the urine.
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Figure 4-2. Increased urinary markers of oxidative stress and oxidative DNA damage in
aged iPLA2y -/- mice. Urine was collected for 24 hr from 2 and 13 month old male iPLA2y KO
and WT mice. Urinary 8-isoprostanes (A) and 8-0HdG (B), markers of oxidative stress and
oxidative DNA damage respectively, were quantified using an ELISA assay kit and normalized to
urine creatinine. Values are mean (pg/mg creatinine) ± SE for 8-isoprostanes and mean (ng/mg
creatinine) ± SE for 8-0HdG. Means highlighted with an asterisk denotes that the mean of KO
animals is significantly different from the mean of WT animals within the age group (N=3-7, p<
0.05).

To assess kidney specific oxidative DNA damage, we stained the kidney tissue for 8OHdG"'using immunohistochemistry. There was a 2-fold increase in 8-0HdG staining in
KO mice at 2 and 13 months compared to WT age-matched control animals (Fig. 4-3A
and B, and Fig. 4-4). Interestingly, 8-0HdG staining was more pronounced in the cortex
and proximal tubules with little evidence of 8-0HdG staining in glomeruli.
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B

A

2 months

13 months

Figure 4-3. Kidney specific oxidant injury in iPLA2Y -/- mouse kidney cortex.
Increased oxidative DNA damage. Immunohistochemistry using an antibody specific to
8-hydroxy-2'-deoxyguanosine (8-0HdG) was performed on sections of 2 month old (A)
and 13 month old (B) iPLA2y WT and KO mouse kidney cortex. "G" denotes glomeruli
and arrows point to 8-0HdG stained nuclei. Note: nuclei stained for 8-0HdG are present
mostly in proximal tubule segments and not in glomeruli.
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Figure 4-4. Quantification of nuclei stained for 8-0HdG. Darkly stained nuclei were
counted per field in a double-blinded fashion on sections of 2 and 13 month iPLA 2y WT
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and KO mouse kidney cortex. Data are expressed as stained nuclei per field (25X) and
are presented as means ± SEM.

We measured thiobarbituric acid reacting speCIes (TBARS), a marker of lipid
peroxidation, in mouse kidney cortex.

There were no differences in TBARS formation

in KO and WT kidney cortex at 2 months of age. However, kidney cortex of 13 month
iPLA2y KO mice exhibited 1.7-fold higher TBARS content than 13 month WT controls
(Fig. 4-5).

*

400
300
200

o

Figure 4-5. Increased lipid peroxidation (TBARS). Kidney cortex of 2 and 13 month
male iPLA2y WT and KO mice were isolated and thiobarbituric acid reacting species
(TBARS) were measured as described in Materials and Methods section. Data (nmol/g
wet kidney cortex) are presented as mean ± SEM. Means highlighted with an asterisk
denotes that the mean of KO animals is significantly different from the mean of WT
animals within the age group.
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To assess the effects of genetic ablation of iPLA2Y on lipid homeostasis, we performed
lipidomic analysis of urine from 13 month old WT and KO mice using ESI-MS/MS. The
intensities of phospholipid species with mlz values of 790.6, 792.5 and 794.4 were
decreased in KO mice compared to WT controls and were identified as 38:6, 38:5 and
37:5 phosphatidylcholine, respectively (Fig. 4-6). Analysis of urine fatty acid using ESIMS revealed no changes in "palmitic, linoleic, stearic or arachidonic acid between 13
month WT and KO mice urine (data not shown).

However, there were significant

increases in intensities at mlz values of 128.7, 143.7 and 178.4 in KO mice urine
compared to WT controls (Fig. 4-6). Analysis using Lipid Maps (www.lipidmaps.org)
and subsequent MS (ESI-MS/MS) suggested that these species are fatty acids contain 610 carbons with methyl or keto additions.

In summary, genetic ablation of iPLA2Y

decreased phosphatidylcholine species and increased fatty acids with methyl or keto
additions in mouse urine.
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Figure 4-6. Effect of genetic ablation of iPLAty on phospholipid and fatty acid
homeostasis in mice urine. Urine was collected for 24 hr from 13 month old male
iPLA2¥ KO and WT mice and analyzed for phospholipids and fatty acids using ESI-MS.
Data are normalized to total ion count and mlz are those identified in the negative (128.7,
147.7 and 178.4) and positive (790.6, 792.5 and 794.4) modes. The identities for these
lipids are indicated in the graph and are based on theoretical m/z value in Lipid Maps
(www.lipidmaps.org) and subsequent MS/MS analysis. Data are presented as the means
± SD of 3-6 separate mice and means highlighted with an asterisk denotes a significant
difference from WT animals.

To assess the effect of genetic ablation of iPLA2¥ on mitochondrial respiratory enzymes,
we measured protein levels of NDUFB8 (Complex I), COX-1 (Complex IV), and ATP
synthase

~

(Complex V) of the electron transport chain (ETC). ATP Synthase

~

and

NDUFB8 are nuclear encoded, while COX-1 is mitochondrial encoded. There was a 1.5fold increase in NDUFB8 protein expression in KO mice kidney cortex in 2 and 13
month animals compared to 2 month WT controls (Fig. 4-7A and B). COX-1 protein
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expression increased by 50% in KO mice kidney cortex at 2 months compared to controls
and trended to increase at 13 months.

In contrast, A TP synthase

~

protein expression

decreased by '"'-'50% in 2 month KO animals compared to 2 month controls, but returned
to control levels at 13 months. In summary, genetic ablation of iPLA2y increased the
expression ofNDUFB8 (Complex I) and COX-I (Complex IV), but not ATP synthase

~

(Complex V).

A

8
2 Month
WT

KO

13 Month
WT

KO

~month~WT

NDUFB8

_1
month
i• c:::::;a
"". 32 m,on
. t".h.WT
K,0
c:::::J 13 month KO

I

ATPIl
COX. . 1

"

GAPDH
Figure 4-7. Effect of genetic ablation of iPLAty on mitochondrial respiratory
proteins in 2 and 13 month old mice kidneys. (A) Expression of mitochondrial
respiratory proteins (NDUFB8, COX-I, and ATP Synthase ~) in kidney cortex of 2 and
13 months old male iPLA2y KO and WT mice was examined by immunoblot analysis
(representative). (B) Data were normalized by GAPDH protein expression (internal
control) and presented as mean ± SEM fold change over control (2 month WT animals).
Bars with different superscripts are significantly different from each other (N = 3-7,
p<0.05).

Oxidative stress and subsequent loss of mitochondrial function, reduced mitochondrial
efficiency, and increased mitochondrial DNA (mtDNA) damage and mutation are
believed to be major components of aging [165]. We used real-time PCR to assess the
effect of genetic ablation of iPLA2y and aging on kidney cortex mtDNA copy number.
Mitochondrial copy number increased with age and KO mice exhibited greater
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mitochondrial copy numbers than WT mice at 2 month; this trend was sustained at 13
months (Fig. 4-8).
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Figure 4-8. Increased mitochondrial copy number in aged iPLAty -/- mice kidney
cortex. DNA was isolated from kidney cortex of 2 and 13 month old male iPLA2y KO
and WT mice and analyzed by real-time peR for relative quantities of mitochondrialencoded ND6 gene and normalized to nuclear-encoded tubulin gene. Data are presented
as the means ± SEM fold change over control (2 month WT animals). Bars with different
superscripts are significantly different from each other (N = 3-7, p<0.05).

Upregulation of antioxidant enzyme stress response pathways are believed to be a
compensatory mechanism by which cellular systems maintain function and viability
during aging and increased oxidant stress, and mRNA levels of antioxidant enzymes are
markers of oxidant stress response in the kidney [166-168]. Glutathione peroxidase 4
(GPx4), a phospholipid hydroperoxidase, and peroxiredoxin 6 (Prdx6), a member of
thiol-specific antioxidant enzyme family with both glutathione peroxidase and
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phospholipase A2 activity, are antioxidant enzymes that reduce lipid hydroperoxides and
are thought to play a role in lipid peroxidation-induced oxidant stress response and
regulation of phospholipid turnover [169-171]. Glutathione reductase 1 (GR1) converts
oxidized glutathione to glutathione but does not have lipid hydroperoxidase activity
[172]. To assess the antioxidant enzyme stress response following iPLA2y ablation, we
measured mRNA expression of these enzymes in WT and KO animals at 2 and 13
months of age using real-time PCR (Fig. 4-9). There was a 3-fold increase in GPx4
mRNA expression in 2 month iPLA2Y KO mice compared to 2 month control animals
(Fig.4-9A). At 13 months, there was a 2-fold increase in both KO and WT mice GPx4
mRNA expression compared to 2 month WT controls.

Conversely, Prdx6 mRNA

expression decreased by 60% in 2 month KO mice compared to 2 month controls (Fig. 49B). There were no differences in Prdx6 mRNA levels between 13 month KO and
control mice, and these levels were similar to those observed in 2 month controls. There
were no differences in GRI mRNA levels between KO and WT mice at either age (Fig.
4-9C). In summary, genetic ablation of iPLA2y resulted in a compensatory increase in
GPx-4 and a decrease in Prdx6 at 2 months of age, but no changes in GRI mRNA
expressIon.
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Figure 4-9. Effect of genetic ablation of iPLA2y on antioxidant stress response proteins
mRNA expression in 2 and 13 month old mice kidney cortex. mRNA was isolated from 2 and
13 month old male iPLA2y KO and WT mice kidney cortex and analyzed by real-time peR for
relative quantities of (A) Glutathione Peroxidase 4 (GPx4), (B) Peroxiredoxin 6 (Prdx6) and (C)
Glutathione Reduction 1 (GR1). Data were normalized to tubulin mRNA expression (internal
control) and presented as mean ± SEM fold change over control (2 month WT animals). Bars
with different superscripts are significantly different from each other (N = 3-7, p<O.05).

Discussion

We previously demonstrated in primary cultures of renal cells that pharmacological
inhibition of iPLA2y potentiated oxidant-induced lipid peroxidation, ER Ca2+ release,
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mitochondrial permeability transition, and renal cell death [68, 97-98, 161]. Genetic
ablation of iPLA2y using shRNA resulted in increased lipid peroxidation, loss of cell
viability, and increased vulnerability to oxidant stress in renal cells [116]. These studies
revealed the protective role of iPLA2y in renal cells and implicated the enzyme in
putative membrane remodeling/repair pathways.

Mancuso et al. showed increased susceptibility to cardiac stress, cognitive dysfunction,
mitochondrial dysfunction (heart, brain, and skeletal muscle) and loss of lipid
homeostasis in mice null for iPLA2y, and Y oda et al. showed increased lipid
peroxidation, loss of lipid homeostasis, mitochondrial dysfunction, and induction of
oxidant-stress related proteins in skeletal muscle [134-136, 141].

Together, these

findings support our previous data revealing iPLA2y as a protective enzyme of oxidative
stress, and provide evidence that impairment of iPLA2y in vivo results in increased
oxidant stress, mitochondrial dysfunction, and organ dysfunction. Because oxidant injury
is a major component of age-related loss of kidney function, the goal of the present study
was to elucidate the role of iPLA2Y in age-related renal oxidant injury.

To determine if genetic ablation of iPLA2y resulted in age-related loss of kidney function,
several parameters of kidney function were monitored, including serum creatinine
concentration and urinary creatinine clearance.

Genetic ablation of iPLA2y was not

sufficient to decrease these clinical markers of kidney function.

However, creatinine

measurements have inherent limitations in measuring kidney function and more sensitive
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measures of kidney function have long-been sought [173]. Urinary NGAL, although a
more sensitive measurement of acute kidney injury [174], is not an effective marker of
chronic kidney injury or impairment [175], and there were no age or phenotype related
changes in urinary NGAL excretion (data not shown). However, the absence of increased
NGAL excretion should be interpreted cautiously [176].

Despite no changes in clinical markers of kidney function in young and aged mice,
kidney histology in 2 month old mice exhibited loss of brush border and tubular
degeneration.

These findings are suggestive of tubular dysfunction in 2 month old

iPLA2y ablated mice that is not sufficient to overcome the reserve capacity of the kidney.
Similarly, greater than a 50% loss of function of kidney cortical tissue is often necessary
to lead to clinical markers of kidney dysfunction in humans, such as increased serum
creatinine [173]. Interestingly, there were no remarkable differences in gross histology
between KO and WT animals at 13 months, which suggests a compensatory response and
recovery of tubular structure. Similarly, genetic ablation of iPLA2Y in the brain also
showed no differences between KO and WT animals in H&E staining in aged animals,
but immunohistochemistry revealed small ubiquitin-positive inclusions suggesting
pathology.

Our in vitro studies using renal cells revealed that iPLA2Y loss results in oxidant injury
(5-10). Here, we show that genetic ablation of iPLA2y results in kidney oxidant stress in
vivo. Lipid metabolites in the blood and urine, such as 8-isoprostanes, are markers of

oxidative stress [1 77] and excretion of 8-isoprostanes was increased in aged iPLA2Y KO
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animals. 8-isoprostane is a prostaglandin-F2-like compound produced by free radicalcatalyzed peroxidation of arachidonic acid in vivo. Additionally, iPLA2y KO animals
exhibited increased kidney cortex lipid peroxidation as measured by TBARS assay,
revealing kidney specific oxidant injury. To our knowledge, these data are the first to
reveal genetic ablation of iPLA2Y results in kidney lipid peroxidation in vivo.

To further characterize iPLA2y-induced oxidant injury in the kidney, we stained for 8OHdG. 8-0HdG is a marker of oxidative DNA damage and oxidative stress and can be
measured in serum, urine, and tissue [112, 178]. Unbound 8-0H dG is freely filtered by
the kidney and accumulates in the urine.

Organs with limited cell turnover, such as

kidney, heart, brain, and liver, accumulate 8-0HdG with oxidant injury, and 8-0HdG in
the urine is proportional to 8-0HdG levels in the tissues and reflects multi-organ
oxidative DNA damage. The increase in 8-0HdG excretion in aged iPLA2¥ KO animals
suggests increased oxidant injury. This hypothesis is supported by the increase in 8OHdG staining in the kidney cortex of aged iPLA2¥ KO animals. These data reveal that
genetic ablation of iPLA2Y results in both lipid peroxidation and oxidative DNA damage
in mouse kidney cortex.

Our in vitro studies in renal cells revealed that iPLA2Y mediates fatty acid release and
maintenance of phospholipid homeostasis during oxidative stress [113, 116, 161]. In this
study, we measured urinary levels of phospholipids and fatty acids. While few
phospholipid species were identified in mouse urine, phospholipid species (38:6, 38:5
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and 37:5 phosphatidylcholine) were decreased in iPLA2y KO animals compared to
controls. These data provide evidence that these phospholipids may be the downstream
targets of iPLA2y ablation-induced oxidative stress, substrates of iPLA2y activity, and/or
are the result of iPLA2y-mediated phospholipid repair. Similarly, our previous studies
revealed that iPLA2Y knockdown increased only a few

phospholipids (one

phosphatidylcholine) in renal cells out of the 267 mlz values studied [116], and inhibition
of iPLA2y in isolated mitochondrial and ER prevented the release of plasmenylcholine
and phosphatidylcholine substrates [98].

The 6-10 carbon fatty acids with methyl or keto additions, increased in iPLA2y KO
animals, likely represent lipid peroxides or oxidized fatty acids. This finding agrees with
our previous studies in micro somes, which showed that oxidant stress increased the
release of unsaturated andlor oxidized fatty acids and iPLA2y mediated their release
[161]. These findings provide strong evidence that genetic ablation of iPLA2Y leads to
alterations in fatty acid and phospholipid homeostasis. Together, these findings, along
with increased urinary 8-isoprostanes and increased TBARS content in kidney cortex of
iPLA2y KO animals, provide evidence that genetic ablation of iPLA2y results in lipid
peroxidation in vivo in the kidney.

Mitochondria are both producers and targets of oxidative stress. Protein analysis revealed
that iPLA 2y ablation induced changes in renal mitochondrial respiratory proteins (ATP
synthase

~,

NDUFB8, and COX1).

These changes likely reflect a compensatory
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response to oxidative stress to maintain cell and tissue viability. NDUFB8 and COX-I are
components of Complex I and IV, respectively, and oxidant-induced dysfunction of these
enzymes can result in electron leak leading to the formation of superoxide radicals and
further ROS production [179-180]. In contrast, ATP synthase

p (Complex V) couples 02

consumption by the electron transport chain with ADP phosphorylation [179].
Interestingly, both NDUFB8 and COX-I proteins and mtDNA copy number are
increased, or trend to increase, in iPLA2Y KO mice compared to control animals.
Increased NDUFB8, COX-I, and mtDNA copy number, may reflect a compensatory
increase in mitochondrial number andlor recovery of function necessary to maintain cell
and tissue viability[165].

In contrast to NDUFB8 and COX-I, ATP synthase

p protein expression decreased in 2

month KO mice, but recovered at 13 months in KO animals. The reason for this decrease
at 2 months is not clear. It may be the result of direct damage, or a compensatory
response to reduce ATP production in the presence of increased NDUFB8, COX-I and
mtDNA.

Mancuso et al. demonstrated inefficient Complex IV O2 reduction suggesting

mitochondrial dysfunction in cardiac mitochondria of 4-6 month old KO animals,
supporting this hypothesis.

Return of ATP synthase

~

protein levels and sustained

increases in Complex I and IV enzymes in 13 month KO animals is suggestive of an
adequate compensatory response to maintain ATP production capacity and therefore
tissue viability. Regardless, these findings provide strong evidence that iPLA2y ablationinduced oxidant injury disrupts electron transport chain complexes and results in a
compensatory response.
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Several other compensatory pathways are required to maintain cellular viability under
oxidant stress such as the upregulation of antioxidant enzyme stress response pathways
[166]. The increase in GPx4 mRNA in iPLAty KO mice supports the conclusion that
genetic ablation of iPLA2y induces a compensatory response in antioxidant enzymes.
GPx4 is responsible for the majority of lipid hydroperoxidase activity in mammalian cells
at physiological pH [166].

It is interesting that mRNA for this gene increased in

correlation with increases in 8-isoprostanes and oxidized lipids.

In contrast to GPx4, level of Prdx6 decreased in KO mice at 2 months. Prdx6, has both
lipid hydroperoxidase activity and phospholipase A2 activity, but the hydroperoxidase
activity is 40-fold greater than its phospholipase activity at physiological pH [169-171].
Other studies revealed that Prdx6 is regulated by ERK and p38 pathways and these
pathways are also implicated in iPLA2 regulation as demonstrated by an upregulation of
both iPLA2 and Prdx6 with PMA treatment and, conversely, knockdown of iPLA2
increased MAPK activation [181-182].

Our data suggests that common signaling

pathways may exist between Prdx6 and iPLA2y and these findings should be further
explored.

These data showing genetic ablation of iPLA2y does not effect GR1 mRNA expression
but alters the expression of GPx4 and Prdx6, supports the hypothesis that iPLA2¥ ablation
induced lipid peroxidation and not an overall increase in redox cycling under these
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conditions. Similarly, Yoda et al. reported increased MDA content and the induction of
antioxidant enzymes in the skeletal muscle of mice genetically ablated of iPLA2y.

These data reveal that genetic ablation of iPLA2y results in oxidant injury (lipid
peroxidation, oxidative DNA damage) that coincides with a disruption of mitochondrial
respiratory protein expression and loss of lipid homeostasis in the kidney. Additionally,
these studies reveal that genetic ablation of iPLA2Y induces compensatory responses to
oxidative stress, such as increased mtDNA, modulation of mitochondrial respiratory
proteins, and upregulation of oxidant stress response pathways. Despite the increase in
oxidative stress in the kidney, iPLA2y ablation-associated oxidant injury does not appear
to be great enough to overcome kidney reserve and regenerative capacity as iPLA2Y
ablated mice do not exhibit greater loss of kidney function at 13 months of age. It should
be pointed out that further studies are needed in older mice to fully assess the effect of
iPLA2y ablation on aging and oxidative stress. Interestingly, Mancuso et al. showed that
ablation of iPLA2y alone was not sufficient to cause cardiac dysfunction, but a
subsequent insult, transverse aortic constriction, revealed cardiac dysfunction in iPLA2y
KO mice [136]. Similarly, age-associated changes in kidney structure and function are
not always sufficient to cause kidney dysfunction, but it is believed that these changes
make the kidney more vulnerable to subsequent insults (ie. ischemialreperfusion-, drug-,
and toxicant injury) [183-184]. A subsequent kidney insult, such as ischemialreperfusion
or toxicant injury, may reveal kidney dysfunction in KO mice.
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Chapter 5
Conclusions and Future Directions

Conclusions

In conclusion, acute kidney injury and chronic kidney disease are becoming more
prevalent and have high morbidity and mortality that have been unchanged for many
years. Current therapeutics targeted towards preventing or treating kidney injury and
disease have been unsuccessful. Calcium-independent phospholipase A 2y (iPLA2Y) is one
of seven Ca2+-independent PLA2 enzymes and represents a potential therapeutic target in
kidney disease [81].

Our studies in renal cells showed that iPLA2y has a unique

subcellular localization in that its expression and activity were found in both the
endoplasmic reticulum (ER) and the mitochondria, while

iPLA2~

activity was not present

[68, 97-98]. We also determined that iPLA2y has divergent roles in cell injury and death,
which may be explained by unique roles and functions within subcellular compartments
[81]. Specifically, iPLA2Y is protective during oxidant-induced necrotic cell death, but
seems to mediate apoptosis-induced cell death. Additionally, iPLA2Y in mitochondria
plays a protective role during oxidant-induced lipid peroxidation and subsequent
mitochondrial swelling, but seems to mediate Ca2+ induced mitochondrial swelling via
arachidonic acid signaling. Unfortunately, lack of organelle specific inhibitors of iPLA2y
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limited studies to isolated organelles and studies in RPTC were not able to distinguish the
respective contributions of ER- and mitochondrial- iPLA2¥. However, recent studies in
our laboratory using iPLA2¥-specific shRNA to decrease iPLA2¥ activity and expression
in RPTC decreased ER- iPLA2¥ prior to mitochondrial- iPLA2¥. These studies confirmed
role of iPLA2¥ in preventing lipid peroxidation and preserving mitochondrial function
and viability under basal conditions [116].
mitochondrial
respiration,

More importantly, while the loss of

iPLA2¥ was correlated with decreased mitochondrial uncoupled

these

studies pointed to

ER- iPLA2Y in the

lipid peroxidation

repair/prevention pathway because knockdown of ER- iPLA2¥, and not mitochondrialiPLA2Y, was correlated with increased lipid peroxidation. However, no studies have
elucidated the role of iPLA2y in the ER nor has the mechanism by which iPLA2y
preserves phospholipid homeostasis been determined. The goals of these studies were to
elucidate the role of ER- iPLA2Y in oxidant-induced ER lipid peroxidation, loss of lipid
homeostasis, Ca2+ release and renal cell death.

Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular
Ca2+, and its release is an important trigger of physiological and pathophysiological
processes, including signaling and cell death pathways. Previous work in our laboratory
revealed the importance of ER Ca2+ in toxicant-induced necrotic renal proximal tubular
cell (RPTC) death. The studies presented here focus on RPTC necrotic cell death. In
order to ultimately elucidate the role of iPLA2¥ in toxicant-induced ER Ca2+ release and
necrotic RPTC death, we needed to develop an assay to visualize ER Ca2+ release in
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RPTC. Prior methods of monitoring ER Ca2+ required extensive loading techniques,
disruption of cell membranes, and/or genetic manipulation of cells to express Ca2+
sensitive proteins. These techniques were not ideal because of our use of primary cells
and employing these methods would likely further disrupt RPTC physiology.

The

purpose of this study (Chapter 2) was to evaluate the use of confocal microscopy and
Fluo5F, a low affinity Ca2+ indicator, to directly monitor changes in RPTC ER Ca2+.
Flu05F staining reflected ER Ca2+, resolved ER structure, and showed no colocalization
with tetramethyl rhodamine methyl ester (TMRM), a marker of mitochondrial membrane
potential. These data provide evidence that confocal microscopy and Flu05F are useful
and effective tools for directly monitoring ER Ca2+ in intact cells.

These studies

furthered our understanding of RPTC ER Ca2+ stores and Ca2+ release-induced
mitochondrial depolarization. This assay would later be used to elucidate the role of
iPLA2y in oxidant-induced ER Ca2+ release in RPTC.

Oxidant-induced lipid peroxidation and cell death are major components of ischemiareperfusion and toxicant injury. Our present studies reveal the role of ER- iPLA2Y in
oxidant-induced ER lipid peroxidation, Ca2+ release, and cell death in isolated ER
(micro somes) and RPTC (Chapter 3). We developed assays using cis-parinaric acid, a
lipid moiety that loses fluorescence with oxidation, and Fluo-4, a Ca2+ -sensitive probe, to
monitor microsomal lipid peroxidation and Ca2+ release, respectively.

Traditional

methods of measuring microsomal Ca2+ release utilized radioactive 45Ca and isolation
filters.

These methods were cumbersome, required relatively large amounts of

microsomes, and lacked the ability to continuously measure Ca2+ release in real-time.
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The use of cis-parinaric acid and fluo-4 allowed for the measurement of both lipid
peroxidation and Ca2+ release in real-time under similar conditions. Oxidant, tert-butyl
hydroperoxide (TBHP), caused ER lipid peroxidation and Ca2+ release in isolated rabbit
kidney cortex microsomes.

ER- iPLA2y inhibition, using bromoenol lactone (BEL),

potentiated both oxidant-induced ER lipid peroxidation and Ca2+ release. These finding
correlated with our studies in mitochondria showing that mitochondrial- iPLA2Y
prevented oxidant-induced lipid peroxidation and mitochondrial swelling. Additionally,
the initiation of lipid peroxidation occurred prior to microsomal Ca2+ release and these
studies excluded the role mitochondria and mitochondrial-iPLA2Y.

Together, these

findings provide evidence that ER Ca2+ release is the result of lipid peroxidation- induced
membrane disruption and not signaling.

PLA2 enzymes catalyze the hydrolysis of fatty acids at. the sn-2 position of
glycerophospholipids resulting in the production of a free fatty acid and a
lysophospholipid. Fatty acids at the sn-2 position tend to be unsaturated and are therefore
more vulnerable to oxidative stress.

PLA2s were hypothesized to play a role in

membrane remodeling/repair by preferentially cleaving damaged (oxidized) fatty acids
from the membrane and allowing the re-esterification of native (non-oxidized) fatty acids
and lysophospholipid. We utilized electrospray ionization-mass spectrometry (ESI-MS)
to investigate the role of ER- iPLA2Y in oxidant-induced ER fatty acid release. Fatty acid
assessment revealed that ER- iPLA2Y mediates the TBHP-induced release of arachidonic
acid (20:4), linoleic acid (18:2), and their oxidized forms (18:2-0H, 18:2-00H, 20:4116

OH, 20:4-00H, 20:4-(OH)3). These findings provide evidence that ER- iPLA2Y prevents
ER Ca2+ release by mediating the release of unsaturated and/or oxidized fatty acids and
thereby maintaining ER membrane integrity.

Additionally, these findings, to our

knowledge, are the first to connect PLA2 activity, its role in membrane remodeling/repair,
and the pathophysiological consequences of the loss of PLA2 activity with respect to
membrane repair.

We then demonstrated in intact cells that iPLA2y inhibition also accelerated oxidantinduced ER Ca2+ release in RPTC using the methods developed in Chapter 2. To connect
oxidant-induced ER Ca2+ release with necrotic cell death, we carried out studies using
flow cytometry. Depletion of RPTC ER Ca2+ stores with thapsigargin, an ER Ca2+ pump
inhibitor, prior to TBHP exposure reduced necrotic cell death and blocked the
potentiation of TBHP-induced necrotic cell death by BEL. These data provide strong
evidence that ER- iPLA2y protects renal cells from oxidant-induced necrotic cell death by
preventing ER Ca2+ release.

These findings, along with the studies in microsomes,

provide evidence that ER- iPLA2Y releases unsaturated and/or oxidized fatty acids during
oxidant stress to preserve ER membrane integrity and prevent ER Ca2+ release, thereby
preventing necrotic cell death. These studies, to our knowledge, are the first elucidate the
mechanism by which ER- iPLA2Y is cytoprotective during oxidative stress.

We tested this hypothesis in vivo using mice genetically ablated of iPLA2y (KO mice)
and investigated its role in age-related renal oxidant injury. To determine oxidant injury,
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we measured urInary 8-isoprostanes and 8-hydroxy-2' -deoxyguanosine (8-0HdG),
biomarkers of lipid peroxidation and oxidative DNA damage, respectively.

Both 8-

OHdG and 8-isoprostanes increased in aged KO mice. These date provide evidence that
genetic ablation of iPLA2y results in increased oxidative stress in KO animals. However,
because these markers in urine reflect global changes in oxidant status, further studies
were required to elucidate the role iPLA2y in the kidney, specifically.

Interestingly, urInary lipidomic analysis in KO animals uSIng ESI-MS demonstrated
decreases in phospholipid species 38:6, 38:5 and 37:5 phosphatidylcholine and increases
in 6-10 carbon fatty acids, with methyl or keto additions. These findings correlated with
our studies in microsomes (Chapter 3) demonstrating iPLA2y is cytoprotective by
preventing lipid peroxidation and preserving membrane homeostasis. Previous studies
using shRNA to knockdown iPLA2Y in RPTC demonstrated a similar build-up of
phosphatidylcholine containing phospholipids. These findings provide strong evidence
that the mechanism by which iPLA2Y is protective in vitro is physiologically relevant in

vivo.

To further investigate the role of iPLA2Y in kidney oxidant stress in vivo, we measured
kidney specific oxidant injury. Our findings that 13 month KO mouse kidney cortex
exhibited higher lipid peroxidation and 8-0HdG staining confirmed kidney specific
oxidant injury. These findings were correlated with changes in renal mitochondrial
respiratory proteins ATP Synthase

B, NDUFB8,

and COX-I, increases in mitochondrial

DNA copy number, and increases in GPx4 mRNA expression in KO mice. Increased
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mitochondrial DNA copy number is thought to be a compensatory response to oxidative
stress to maintain mitochondrial number and function and GPx4 is an antioxidant enzyme
that contains lipid hydroperoxidase activity and is believed to be a component of the
membrane remodeling/repair pathway. Interestingly, genetic ablation of iPLA2¥ did not
result in loss of kidney function. It is likely that iPLA2¥ ablation, as expected, induced
oxidant injury, but resulted in a compensatory response to maintain tissue viability as
evidenced by mitochondrial changes and increases in oxidant stress response pathways.
Collectively, these data support our hypothesis that ER- iPLA2y protects renal cells from
oxidant-induced necrotic cell death by preventing ER lipid peroxidation, preserving ER
membrane integrity, and blocking ER Ca2+ release and loss of Ca2+ homeostasis. These
studies revealed ER- iPLA2¥ preferentially cleaves unsaturated and/or oxidized fatty
acids under oxidant stress and provides the mechanism by which it is protective. We also
confirmed iPLA2¥ plays a similar and crucial role in oxidative stress in vivo. Together,
these studies have elucidated the role of iPLA2¥ in oxidant-induced renal cell death,
revealed the mechanism by which ER- iPLA2¥ is cytoprotective, and has furthered our
understanding of kidney physiology and pathophysiology in the setting of aging and
oxidant injury. iPLA2y represents a potential therapeutic target to prevent acute kidney
injury in patients at high risk or hasten recovery of kidney function following AKI.
Further understanding of the role of iPLA2y in chronic kidney disease may elucidate
therapeutics that would prevent the progression of CKD to end-stage renal disease and
failure.

119

Future Directions

The studies presented here focus on the role of iPLA2y in oxidant-induced necrotic cell
death and have uncovered several questions that require further investigation.
Additionally, the role of iPLA2y in apoptosis-induced renal cell death or its role in cell
signaling was not investigated within the scope of these studies. Potential investigations
will be presented here.
Our previous studies demonstrated iPLA2¥ mediates cisplatin-induced renal apoptotic cell
death and studies in mitochondria demonstrated iPLA2y mediates Ca2+- induced
mitochondrial swelling through an arachidonic acid-dependent initiation of mitochondrial
pore transition. Because apoptosis is thought to be a major component of age-related loss
of kidney function and thought to playa role in the progression of chronic kidney disease
to end-stage renal failure, elucidating the role of iPLA2Y in apoptosis-induced cell death
may uncover potential therapeutics in renal injury.

The assays developed and

experimental methods utilized during the course of these experiments may be used to
further investigate the role of iPLA2y in apoptosis. Specifically, renal cell imaging using
confocal microscopy to monitor mitochondrial membrane potential and Ca2+ dynamics
may help to elucidate the role of iPLA2Y in cisplatin-induced renal cell apoptosis.
iPLA2¥ regulation was not investigated during the course of these experiments. Our
previous studies demonstrate phorbol 12-myristate 13-acetate (PMA), a protein kinase C
(PKC) activator, increased ER-iPLA2¥ activity and potentiated cisplatin-induced
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apoptosis [112]. Interestingly, RPTC exposed to PMA activates only ER-iPLA2y and not
mitochondrial iPLA2y (Figure 5-1). These findings suggest that ER-iPLA2y activity may
be more closely regulated by phosphorylation status. Furthermore, exposure of RPTC to
PKCE VI-2 specifically decreased ER-iPLA2y activity and prevented PMA-induced
activation of ER-iPLA2y.

Together these findings suggest that ER-iPLA2y, and not

mitochondrial iPLA2y, is regulated by PKCE-induced phosphorylation and ER-iPLA2y
activity may be specifically manipulated while mitochondrial- iPLA2y remains
unchanged.

A. RPTC Microsornes

B. RPTC Mitochondria
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Figure 5-1. Effect of PMA and PKCE inhibitor on ER and mitochondrial iPLA2y
activity in RPTC. RPTC were exposed to the PKCE VI-2 inhibitor (Inh, 20 J.lM) for 1
hr and 24 hr or PMA (100 nM for 30 minutes) in the presence and absence of the PKCE
VI-2 inhibitor (1 hour pretreatment). ER and mitochondrial fractions were isolated from
RPTC and iPLA2 activity measured using synthetic plasmenylcholine (16:0, eH] 18: 1).
Data are presented as the mean + SEM. Means with different superscripts are
significantly different from each other, p < 0.05, n=4.

It has been proposed that iPLA2y activity and function is regulated by phophorylation and
differential expression of splice variants. Analysis of the amino acid sequence of iPLA2y
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showed that there are many potential serine, threonine and tyrosine phosphorylation sites
[96, 185]. However, the phosphorylation of specific amino acids on iPLA2y has not been
has not been investigated and little is known of the kinases and phosphatases involved.
Experiments directed at elucidating the mechanism by which iPLA2y is regulated by
phosphorylaton need to be addressed.

Our studies in microsomes presented in Chapter 3 revealed several interesting findings
using ESI-MS. The goal of these studies were to elucidate the mechanism by which ERiPLA2y prevents lipid peroxidation, and these studies demonstrated ER-iPLA2Y mediates
the release of unsaturated and/or oxidized fatty acids during oxidative stress. However,
these studies also revealed that inhibition of ER-iPLA2Y by BEL increased the release of
a lipid species at M/z 345. This species may represent 1) a signaling molecule involved in
the initiation of ER Ca2+ release, 2) the build-up of a lipid substrate specifically acted
upon by ER-iPLA2yand/or 3) the byproduct of ER membrane disruption.
investigation

of

this

lipid

moiety

may

iPLA2Y substrate/signaling molecule (Figure 5-2).
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Figure 5-2. Inhibition of iPLA2Y induces the release of lipid (m/z 345) from
microsomes. Released lipids were separated from microsomes using differential
centrifugation, extracted by Bligh Dyer method, injected directly into ESI-Mass
Spectrometer, and analyzed in negative mode. Microsomes were pretreated for 20 min
with BEL or diluent, treated for 30 min with 200 ~M TBHP, and reaction was stopped
and analyzed by ESI-MS.

Our studies in mice genetically ablated of iPLA2Y (Chapter 4) suggest ablation-associated
oxidant injury is not great enough to overcome kidney reserve and regenerative capacity
and iPLA2y ablated mice do not exhibit greater loss of kidney function at 13 months of
age. Interestingly, Mancuso et al. showed that ablation of iPLA2y alone was not sufficient
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to cause cardiac dysfunction, but a subsequent insult, transverse aortic constriction,
revealed cardiac dysfunction in iPLA2y KO mice [136].

Similarly, age-associated

changes in kidney structure and function are not always sufficient to cause kidney
dysfunction, but it is believed that these changes make the kidney more vulnerable to
subsequent insults (ie. ischemialreperfusion-, drug-, and toxicant injury) [183-184]. A
subsequent kidney insult, such as ischemialreperfusion or toxicant injury, may reveal
kidney dysfunction in KO mice. We have developed a model of ischemiaireperfusion
(Figure 5-3) and toxicant injury (Figure 5-4) that may be used to reveal kidney
dysfunction in mice genetically ablate of iPLA2y.
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Figure 5-3. Kidney dysfunction after ischemia-reperfusion injury. Serum creatinine
levels were significantly elevated 24 h after reperfusion, and then slowly decreased
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between 24 hand 144 h without returning to normal levels. Different superscripts above
data points are significantly different from one another (P < 0.05). From Funk and
Schnellmann, 2011 [19].
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Figure 5-4. Renal dysfunction after glycerol-induced myoglobinuria. (A) Serum
creatinine was maximal 24 h after injection, and partially recovered between 24 h and
144 h after injury without returning to normal levels. (B) Urine creatinine was reduced 48
h after injury and remained decreased at 144 h. Urine glucose (C) and NGAL (D) were
elevated 48 h after glycerol injection and remained elevated at 144 h. Different
superscripts above data points are significantly different from one another (P < 0.05).
From Funk and Schnellmann, 2011 [19].

Additional studies are need in KO mice to further elucidate the role of iPLA2Y in oxidant
injury and loss of renal function in vivo. Studies in animals older than 13 months may
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reveal an earlier onset of age-associated loss of kidney function in iPLA2Y ablated mice.
Additionally,

older

KO

animals

should

be

subjected

to

our

model

of

ischemialreperfusion-induced kidney injury and may reveal iPLA2Y ablated animals are
more vulnerable to a subsequent injury. There are several studies of iPLA2Y that require
further investigation and may further our understanding of the role iPLA2y in renal
physiology and pathophysiology, responses of renal cells to oxidant injury, and the
molecular and physiological changes within the aging kidney.
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